US20170174746A1 - Recombinant Bacterium and Uses Thereof - Google Patents
Recombinant Bacterium and Uses Thereof Download PDFInfo
- Publication number
- US20170174746A1 US20170174746A1 US15/369,294 US201615369294A US2017174746A1 US 20170174746 A1 US20170174746 A1 US 20170174746A1 US 201615369294 A US201615369294 A US 201615369294A US 2017174746 A1 US2017174746 A1 US 2017174746A1
- Authority
- US
- United States
- Prior art keywords
- ova
- antigen
- cells
- mice
- recombinant bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 92
- 239000000427 antigen Substances 0.000 claims abstract description 95
- 102000036639 antigens Human genes 0.000 claims abstract description 89
- 108091007433 antigens Proteins 0.000 claims abstract description 89
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 33
- 230000001580 bacterial effect Effects 0.000 claims abstract description 33
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 17
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 17
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 17
- 230000028327 secretion Effects 0.000 claims abstract description 8
- 230000003612 virological effect Effects 0.000 claims abstract description 6
- 239000013598 vector Substances 0.000 claims description 26
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 25
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 241000607142 Salmonella Species 0.000 claims description 19
- 108010069584 Type III Secretion Systems Proteins 0.000 claims description 12
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 9
- 108010051081 dopachrome isomerase Proteins 0.000 claims description 9
- 102000008840 Melanoma-associated antigen 1 Human genes 0.000 claims description 6
- 108050000731 Melanoma-associated antigen 1 Proteins 0.000 claims description 6
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 56
- 210000000172 cytosol Anatomy 0.000 abstract description 40
- 244000052769 pathogen Species 0.000 abstract description 27
- 230000003834 intracellular effect Effects 0.000 abstract description 13
- 210000000680 phagosome Anatomy 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 10
- 230000006044 T cell activation Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 102
- 230000005945 translocation Effects 0.000 description 53
- 108010058846 Ovalbumin Proteins 0.000 description 50
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 47
- 229940092253 ovalbumin Drugs 0.000 description 47
- 210000001744 T-lymphocyte Anatomy 0.000 description 43
- 208000015181 infectious disease Diseases 0.000 description 43
- 230000005867 T cell response Effects 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 32
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000003389 potentiating effect Effects 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 23
- 230000030741 antigen processing and presentation Effects 0.000 description 20
- 230000000890 antigenic effect Effects 0.000 description 16
- 230000002238 attenuated effect Effects 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 14
- 210000004989 spleen cell Anatomy 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 13
- 102000011931 Nucleoproteins Human genes 0.000 description 12
- 108010061100 Nucleoproteins Proteins 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 241001167018 Aroa Species 0.000 description 9
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 9
- 101150037081 aroA gene Proteins 0.000 description 9
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 8
- 102100033467 L-selectin Human genes 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 241000222722 Leishmania <genus> Species 0.000 description 4
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 3
- 241000589562 Brucella Species 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 108091006619 SLC11A1 Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 231100000749 chronicity Toxicity 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 101710088758 23kDa protein Proteins 0.000 description 2
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 2
- 0 C*(C1)C1*=S[C@](C(*)CC(*)C(*)C(C(C(C*)O)(O)O)N=O)C1*CC*[C@@](**CO)*C1 Chemical compound C*(C1)C1*=S[C@](C(*)CC(*)C(*)C(C(C(C*)O)(O)O)N=O)C1*CC*[C@@](**CO)*C1 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700018133 Salmonella Spi1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710142113 Serine protease inhibitor A3K Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 101150028857 phoP gene Proteins 0.000 description 1
- 101150086617 phoQ gene Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464832—Salmonella; Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to recombinant bacterium and uses thereof. More specifically, the invention relates to recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof.
- CD8+ T cells uniquely provide immune-surveillance to the entire body because they recognize targets in the context of MHC class I molecules, which are present in every cell (Bevan, 1995). Furthermore, CD8+ T cells can eliminate infected cells or tumour cells rapidly. Thus, the induction of specific, potent CD8+ T cells is highly desirable for diseases that are caused by intracellular pathogens and tumours.
- Intracellular pathogens induce CD8+ T cell responses; however, the responses are either highly attenuated or the organism itself is highly toxic.
- rapid proliferation of pathogens is countered by rapid presentation of antigen to CD8 + T cells within the first few days of infection and activated CD8 + T cells undergo profound expansion (>1000-fold) within the first week of infection, which results in resolution of infection (Kaech and Ahmed, 2001).
- CD8+ T cells play a key role in mediating immune-surveillance against tumours (Smyth et al., 2000).
- CD8+ T cells play a principal role in controlling intracellular pathogens and tumours.
- rapid induction of memory CD8+ T cells is essential for developing vaccines against tumours or intracellular pathogens.
- CD8+ T cells play a key role against various diseases, their induction is highly tedious. Antigenic proteins injected into hosts in the absence or presence of adjuvants does not lead to the induction of CD8+ T cells (Moore et al., 1988). This is mainly because extracelluar proteins do not gain access to the cytoplasm (cytosol) of antigen-presenting cells (APC) (Rock, 1996). Rather, these extracellular proteins or vaccines are trafficked through specialized intracellular vesicles called phagosomes, which leads to the activation of helper T cells to aid antibody production. For induction of CD8+ T cell responses, the pathogen or the vaccine has to reside within the cytosol of an antigen-presenting cell (Bahjat et al., 2006).
- Salmonella enterica serovar Typhimurium induces rapid death of macrophages and dendritic cells (Hersh et al., 1999; van der Velden et al., 2000) and it has been shown that cross-presentation of ST antigens occurs through dendritic cells (Yrlid and Wick, 2000). Phagosomes have themselves been considered to be competent at promoting cross-presentation (Houde et al., 2003). However, these mechanisms are of little protective value since rapid pathogen elimination is not observed. Cells that are cross-presenting ST antigens don't appear to serve as good targets for CD8 + T cells to mediate their function. Thus, target cell accessibility seems to be the critical difference between direct and cross-presentation.
- Subunit vaccines that consist of purified proteins admixed with adjuvants typically do not induce CD8+ T cell response due to residence of these entities within phagosomes of cells (Bahjat et al., 2006). However, some adjuvants induce CD8+ T cell responses most likely by the cross-presentation pathway (Krishnan et al., 2000). Subunit vaccines are difficult to mass-produce and are faced with numerous technical difficulties including batch to batch variability, quantitation of the antigen-adjuvant ratio, and extensively laborious procedures. To avoid this problem, live vaccines are preferred. However, live vaccines can be either over- or under-attenuated and it is difficult to find the right balance (Raupach and Kaufmann, 2001).
- viral infections such as Lyphochoriomeningitis virus, LCMV
- LCMV Lyphochoriomeningitis virus
- Live bacteria can be considered as an alternative option for vaccine development since antibiotics can be used in case they are not controlled by the host.
- extracellular bacteria do not gain access to the cytosol of infected cells, hence fail to induce CD8+ T cell response (Bevan, 1995).
- intracellular bacteria induce CD8+ T cell response, albeit poor, despite residing within the phagosomes of infected cells, perhaps by cross-presentation (Kaufmann, 1993)—the caveat being that intracellular bacteria (e.g., Salmonella, Mycobacteria, Leishmania ) that reside within the phagosomes of infected cells induce a chronic infection, implying that CD8+ T cells fail to eradicate them from the host (Kaufmann, 1993; Hess and Kaufmann, 1993).
- intracellular bacteria e.g., Salmonella, Mycobacteria, Leishmania
- the present invention relates to recombinant bacterium and uses thereof. More specifically, the invention relates to recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof.
- the present invention provides a recombinant bacterium, comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell.
- the bacterium may be Salmonella, Mycobacteria, Brucella , or Leishmania .
- the recombinant bacterium may be Salmonella.
- the antigen expressed by the recombinant bacteria as just described may be a viral antigen, a bacterial antigen, or a tumour antigen.
- the antigen may be the nucleoprotein of LCMV, tyrosinase related protein 2 (TRP-2), MART-1, melanoma associated antigen 1 (MAGE1), gp100, or Her-2/neu or other viral or bacterial antigens.
- the nucleic acid encoding the antigen may encode a fusion protein comprising the antigen and a translocation domain from a type III secretion system.
- the translocation domain may be YopE, SopE, SptP, or a fragment thereof.
- the chaperone may be SycE or a fragment thereof (such as, but not limited to MKISSFISTSLPLPTSVS, SEQ ID NO:2).
- the fusion protein may optionally further comprise a chaperone.
- the chaperone may be derived from a type III secretion system.
- the chaperone may be SycE or HSP70.
- the nucleic acid may be comprised in a vector.
- the vector may be a pHR vector; in a specific example, the vector may be a modified pHR-241 vector.
- the vector may be modified to remove the sequence of p60/M45, may be optionally further modified to remove the sequence of SycE.
- fusion proteins encompassed by the present invention are those of SEQ ID NO:7 to SEQ ID NO:12.
- the present invention also provides a method of imparting immunity against naturally-occurring bacterium in a subject, the method comprising administering the recombinant bacterium described above to said subject.
- the present invention further provides a method of imparting immunity against tumours in a subject, the method comprising administering the recombinant bacterium described above to said subject.
- the recombinant bacterium may be administered by intravenous, oral, or subcutaneous routes of immunization.
- the present invention also encompasses a use of the recombinant bacterium described herein as a vaccine.
- a novel vaccine vector Salmonella ) is presently provided, wherein a key modification makes the bacterium generate rapid, potent CD8+ T cell response, resulting in self-destruction of the vaccine in vivo, making it highly efficacious, safe and cost-effective at the same time.
- OVA antigen-presentation
- FIG. 1A shows a schematic of the fusion protein constructed, where an antigen (OVA) is fused to YopE, which is then incorporated into the plasmid pHR241 containing the SycE chaperone.
- FIG. 1B shows a schematic of the antigen (OVA) translocation into the cytosol for ST-OVA-T, and the lack thereof for ST-OVA-NT.
- Ag antigen
- OVA ovalbumin
- ST Salmonella Typhimurium
- FIG. 1C shows expression of OVA (by western blot) in the bacterial pellet, supernatant, and the cytosol of spleen cells of mice infected for 24 h with ST-OVA-NT and ST-OVA-T.
- FIG. 2A shows a graph representing the doubling times of the ST-OVA-NT (closed circles) and ST-OVA-T (open circles) bacteria in liquid culture, based on the measurement of OD at 600 nm. Based on these values, the bacteria were found to be similar.
- FIG. 3A shows flow cytometry results of in vitro infection of IC-21 macrophages (H-2 b ) with recombinant bacteria (ST-OVA-NT, ST-OVA-T, or ST).
- ST-OVA-NT IC-21 macrophages
- ST-OVA-T recombinant bacteria
- FIG. 3B shows flow cytometry results of in vivo infection of B6.129F1 mice infected with ST-OVA-NT or ST-OVA-T (Day 5).
- ST-OVA-T-infected mice the majority of transferred OT-1 cells displayed reduced expression of CFSE while OT-1 cells in ST-OVA-NT-infected mice maintained high levels of CFSE expression. Results represent the mean of three mice ⁇ SD per group, and are representative of 2-3 independent experiments.
- FIG. 3C is a graphical representation of the kinetic evaluation of in vivo antigen-presentation.
- ST-OVA-NT infected mice displayed muted and delayed activation of CFSE-labelled OT-1 cells.
- ST-OVA-NT closed circles
- ST-OVA-T open circles).
- FIG. 4A shows the numbers of spleen cells, spleen size at Day 14 ( FIG. 4B ) and bacterial burden ( FIG. 4C ) in resistant (B6.129F1) mice infected with ST-OVA-T or ST-OVA-NT, as well as the percentage ( FIG. 4D ) and numbers ( FIG. 4E ) of OVA-specific CD8 + T cells in the spleen.
- Results represent the mean of three to five mice ⁇ SD per group and are representative of three independent experiments.
- ST-OVA-NT closed circles
- ST-OVA-T open circles).
- FIG. 5A shows the OVA-tetramer profile in the spleens of ST-OVA-T- or ST-OVA-NT-infected resistant (B6.129F1) mice at Day 7.
- the expression of CD62L ( FIG. 5B, 5D ) and CD127 ( FIG. 5C, 5D ) on OVA-tetramer+CD8+ T cells is also shown. Results are representative of three independent experiments. These results indicate early generation of memory CD8+ T cells in mice infected with ST-OVA-T. ST-OVA-NT (closed circles); ST-OVA-T (open circles).
- FIG. 6A shows the bacterial burdens in spleen cells of susceptible (C57BL/6J) mice infected with ST-OVA-T or ST-OVA-NT, along with the percentage ( FIG. 6B ) and numbers ( FIG. 6C ) of OVA-specific CD8 + T cells, as well as the frequency of OVA-specific CD8 + T cells evaluated by ELISPOT assay ( FIG. 6D ).
- the specific killing of OVA-pulsed targets in na ⁇ ve mice exposed to OVA-pulsed and control spleen cells is shown if FIG. 6E and F, indicating that ST-OVA-T infection results in rapid induction of antigen-specific CD8+ T cells that can efficiently kill antigen-bearing target cells. Results represent the mean of three to four mice ⁇ SD per group, and two independent experiments. ST-OVA-NT (closed circles); ST-OVA-T (open circles).
- FIG. 7A shows the OVA-tetramer profile in the spleens of susceptible (C57BL/6J) mice infected with ST-OVA-T or ST-OVA-NT at Day 7.
- FIG. 7B shows the expression of CD62L versus CD127 on splenic OVA-tetramer + CD8 + T cells in the ST-OVA-T versus ST-OVA-NT infected mice.
- CD8+ T cells generated with ST-OVA-T infection express high levels of CD127 and CD62L (memory markers). Results are representative of three independent experiments.
- FIG. 8A shows the bacterial burden in spleens of C57BL/6J mice treated with anti-CD4 (clone GK1.5), anti-CD8 (clone 2.43) or Rat IgG isotype antibodies following infection with ST-OVA-T. Results represent the mean of three to four mice ⁇ SD per group. Anti-CD4 and anti-CD8 antibody treatment resulted in near complete elimination of CD4 and CD8+ T cells respectively.
- FIG. 8B shows the bacterial burden in spleens of WT, MHC-I- or MHC-II-deficient mice following infection with ST-OVA-T. These results indicate that the control of bacterial burden in ST-OVA-T infected mice is mediate exclusively by CD8+ T cells. Results represent the mean of five mice ⁇ SD per group.
- FIG. 9A shows the relative numbers of OVA-specific CD8 + T cells in the spleen and peripheral blood ( FIG. 9B ) of B6.129F1 mice infected with wild type (WT) or attenuated ( ⁇ aroA) ST-OVA expressing non-translocated (NT) or translocated (T) OVA.
- WT-OVA-NT closed circles
- WT-OVA T open circles
- AroA-OVA-NT closed inverted triangles
- AroA-OVA-T open inverted triangles.
- FIG. 10A is a graphical representation of the results of prophylactic vaccination with ST-OVA-T in C57BL/6J mice followed by subcutaneous challenge with B16-OVA tumor cells. This protocol resulted in potent protection against tumor challenge.
- Non-infected closed circles
- ST-OVA-T open squares
- FIG. 10B shows a graph of results of therapeutic vaccination with ST-OVA-T in C57BL/6J mice after subcutaneous challenge with B16-OVA tumor cells. Mice receiving ST-OVA-T displayed the best protection against B16 melanoma cells. Protection induced by ST-OVA-T was far greater than that induced by ST-OVA-NT and the another recombinant bacterium, Listeria expressing OVA (LM-OVA). Results represent the mean of five mice ⁇ SD per group. Non-infected (full circles); ST-OVA-T (open squares); ST-OVA-NT (closed triangles); LM-OVA (open diamonds).
- FIG. 11A shows the frequency of CD8+ T cells against a tumour antigen (Trp-2) in the spleens of mice infected with wild-type (WT) or attenuated (aroA) ST-Trp2-T on Day 7.
- FIG. 11B shows the bacterial burden in the spleens of mice at various time intervals post-infection with WT ST-Trp2-T (open squares) or ST-Trp2-NT (closed circles).
- FIG. 11C shows the bacterial burden in the spleens of mice infected with aroA mutant of ST-Trp2-T (open squares) or NT (closed circles).
- FIG. 12A shows the bacterial burden in the spleens of mice infected with translocated or non-translocated aroA-ST expressing another tumour antigen (gp100).
- aroA-gp100-T open squares
- aroA-gp100-NT closed circles
- FIG. 12 B shows the numbers of gp100-tetramer+CD8+ T cells in the spleens of infected mice at various time intervals.
- aroA-ST-gp100-T open squares
- aroA-ST-gp100-NT closed circles).
- FIG. 13A shows the schematic of the fusion constructs.
- FIG. 13B shows the frequency of NP-specific CD8+ T cells in mice infected with ST-NP-T or ST-NP-NT at day 7 post-infection.
- FIG. 13C shows the in vivo cytolytic activity of NP-specific CD8+ T cells on NP-pulsed target cells at day 7 post-infection. Cytolytic activity was evaluated after transferring na ⁇ ve spleen cells (pulsed with media or NP peptide) into infected mice at day 7 and evaluated the killing of peptide-pulsed targets at 24 h post-transfer.
- FIG. 13A shows the schematic of the fusion constructs.
- FIG. 13B shows the frequency of NP-specific CD8+ T cells in mice infected with ST-NP-T or ST-NP-NT at day 7 post-infection.
- FIG. 13C shows the in vivo cytolytic activity of NP-specific CD8+ T cells on NP-pulsed target cells
- FIG. 13D shows the frequency of NP-specific CD8+ T cells in mice infected with aroA-NP-T (black bars) or aroA-NP-NT (white bars).
- FIG. 13E shows the bacterial burden in the spleens at various time intervals. aroA-NP-T (open squares) or aroA-NP-NT (closed circles)
- FIG. 13F shows the influence of antigenic translocation on the induction of inflammation in the spleen. aroA-NP-T (open squares); aroA-NP-NT (closed circles).
- FIGS. 14A-14E shows that truncated YopE is equally effective at inducing CD8+ T cell response.
- FIG. 14A shows the schematic representation of the full length (upper panel) and the truncated YopE (lower panel).
- FIG. 14B shows the OVA-specific CD8+ T cell response in the spleens of mice infected with full YopE or truncated YopE.
- FIG. 14C shows that both the full length and truncated YopE induce the rapid generation of OVA-specific CD8+ T cells expressing memory marker (CD127).
- FIG. 14D shows the inflammation induced (numbers of spleen cells) in mice infected with full length or truncated YopE.
- FIG. 14A shows the schematic representation of the full length (upper panel) and the truncated YopE (lower panel).
- FIG. 14B shows the OVA-specific CD8+ T cell response in the spleens of mice inf
- 14E shows the bacterial burden in the spleens of mice infected with full length or truncated YopE.
- ST-OVA-NT closed circles
- ST-OVA-T open circles
- ST-OVA-tYopE closed triangles
- the present invention relates to recombinant bacterium and uses thereof. More specifically, the invention relates to recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof.
- the present invention provides a recombinant bacterium, comprising a nucleic acid encoding an antigen that is translocated to the cytosol of the host organism.
- the bacterium may be any virulent or attenuated bacterium that resides in the phagosome of macrophages and/or dendritic cells and induces poor T cell activation.
- a bacterium may be, but is not limited to Salmonella, Mycobacteria, Brucella, Leishmania , and the like, which are all intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation, hence causing diseases that are not controlled by the immune system.
- the virulent or attenuated bacterium may be Salmonella .
- Salmonella enterica serovar Typhimurium (ST).
- ST is a highly virulent pathogen that induces gastroenteritis in humans, and typhoid-like disease in mice (Jones and Falkow, 1996).
- ST resistance-associated macrophage proteins
- iv 10 2 )
- ST induces a chronic but non-lethal infection in resistant 129SvJ mice (which express NRAMP).
- F1 hybrids between susceptible and resistant mice (B6.129F1) also harbour a chronic, non fatal, infection (Luu et al., 2006).
- SPI-1 Salmonella pathogenicity island-1 loci
- TTSS type III secretion system
- the two-component regulatory system phoP/phoQ which controls >40 genes (Groisman et al., 1989; Miller et al., 1989), is involved in intracellular survival (Garvis et al., 2001).
- Another pathogenicity island (SPI-2) encodes a second TTSS, mediates resistance to intracellular killing, and is key to virulence (Hensel et al., 1995; Shea et al., 1996).
- the CD8+ T cell response against ST is delayed, which fails to control the bacterium leading to a chronic infection (Albaghdadi et al., 2009).
- aroA mutant of ST was developed as a vaccine against Salmonella (Hoiseth and Stocker, 1981), which induces minimal inflammation and poor immunogenicity (Albaghdadi et al., 2009; Dudani et al., 2008).
- the virulent or attenuated bacterium of the present invention may be the aroA mutant of ST, comprising a vaccine vector modified such that the bacterium resides in the phagosome of infected cells, but translocates antigen to the cytosol.
- Phagosomal localization is considered a major impediment to T cell activation, and the antigenic translocation strategy described herein can be used for other intracellular bacterial vaccine vectors, including Mycobacteria, Brucella or Leishmania.
- recombinant it is meant that the bacterium has been genetically altered or engineered; such genetic engineering may be the inclusion of a recombinant (or artificial) nucleic acid or vector (comprising a nucleic acid) encoding a foreign protein that is an antigen.
- the antigen may be any suitable protein or fragment thereof that is processed and presented efficiently by dendritic cells and/or macrophages resulting in efficient T cell activation.
- the antigen or fragment thereof may be a nascent protein, a bacterial antigen, viral antigen, or a tumour antigen.
- the antigen may be, but is not limited to tyrosinase related protein 2 (TRP-2), MART-1, melanoma associated antigen 1 (MAGE1), gp100, Her-2/neu or other proteins or fragments thereof known in the art.
- proteins may include, but are not limited to ovalbumin, hen egg lysozyme, and myelin basic protein, nuclear protein of LCMV.
- the antigens may be ovalbumin, TRP-2, gp-100, LCMV-NP, or fragments thereof.
- the antigen Upon infection, the antigen is translocated into the cytosol of the host cell (for example macrophages and/or dendritic cells).
- the antigen may naturally translocate to the cytosol, or may be a recombinant protein engineered to do so.
- the antigen may be comprised in a fusion protein that further comprises a translocation domain from a type III secretion system; optionally, the fusion protein may further comprise a chaperone.
- the fusion protein also referred to herein as “fused proteins”, comprising the antigen may be generated via recombinant methods well-known to those of skill in the art.
- the antigen and translocation domain, and the optional chaperone may be joined directly or by a linker; appropriate linkers would be well-known to those of skill in the art.
- translocation domain a protein domain or fragment thereof that directs translocation of a protein from the phagosome to the cytosol of the host cell.
- the translocation domain may be any suitable translocation domain from known type III secretion systems of bacteria, which are well-known to those of skill in the art.
- the translocation domain may be YopE or a fragment thereof.
- YopE is a 23kDa protein comprising a N-terminal secretion domain of approximately 11 amino acids and a translocation domain of at least 50 aa.
- the YopE translocation domain may comprise the sequence:
- the SptP translocation domain may be the SptP protein of ST (Russmann et al., 1998); again, the SptP translocation domain could be the full length protein or a truncated version thereof.
- the SptP translocation domain may comprise the sequence:
- the fusion protein may optionally comprise a chaperone.
- chaperone it is meant a protein that assists in translocation of the immunodominant antigen.
- the chaperone protein may be any suitable protein known in the art, and must be compatible with translocation domain chosen.
- the chaperone may also be from a type III secretion system.
- the chaperone may be SycE.
- SycE is a YopE-specific chaperone that is required for YopE-mediated translocation of fused proteins to the cytosol (Russmann et al., 2001).
- SycE assists in translocation of the fused protein into the cytosol of infected cells through the type III secretion system of ST.
- the SycE chaperone may comprise the sequence:
- the SopE translocation domain has been used in combination with the chaperone protein heat shock protein 70 (Hsp70) to deliver an antigen to the cytosol (Zhu et al., 2010).
- the chaperone may comprise the sequence:
- the inclusion of the chaperone is optional, as the translocation domain, or a fragment thereof, alone may be sufficient to cause translocation of the antigen to the cytosol; for example, and without wishing to be limiting, YopE alone, or an 18-amino acid fragment thereof (MKISSFISTSLPLPTSVS, SEQ ID NO:2) are presently shown to produce the desired effect.
- YopE alone, or an 18-amino acid fragment thereof (MKISSFISTSLPLPTSVS, SEQ ID NO:2) are presently shown to produce the desired effect.
- expression of the endogenous Salmonella chaperone protein InvB is sufficient to mediate the translocation function of SopE (Lee and Galan, 2003).
- the recombinant bacterium comprises a nucleic acid encoding an antigen comprising a fusion protein comprising the sequence of SycE, YopE, and ovalbumin:
- the fusion protein further comprises the sequence of the antigen of interest.
- a substantially identical sequence may comprise one or more conservative amino acid mutations. It is known in the art that one or more conservative amino acid mutations to a reference sequence may yield a mutant peptide with no substantial change in physiological, chemical, or functional properties compared to the reference sequence; in such a case, the reference and mutant sequences would be considered “substantially identical” polypeptides.
- Conservative amino acid mutation may include addition, deletion, or substitution of an amino acid; a conservative amino acid substitution is defined herein as the substitution of an amino acid residue for another amino acid residue with similar chemical properties (e.g. size, charge, or polarity).
- a conservative mutation may be an amino acid substitution.
- Such a conservative amino acid substitution may substitute a basic, neutral, hydrophobic, or acidic amino acid for another of the same group.
- basic amino acid it is meant hydrophilic amino acids having a side chain pK value of greater than 7, which are typically positively charged at physiological pH.
- Basic amino acids include histidine (His or H), arginine (Arg or R), and lysine (Lys or K).
- neutral amino acid also “polar amino acid”
- hydrophilic amino acids having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
- Polar amino acids include serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N), and glutamine (Gln or Q).
- hydrophobic amino acid (also “non-polar amino acid”) is meant to include amino acids exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg (1984). Hydrophobic amino acids include proline (Pro or P), isoleucine (Ile or I), phenylalanine (Phe or F), valine (Val or V), leucine (Leu or L), tryptophan (Trp or W), methionine (Met or M), alanine (Ala or A), and glycine (Gly or G). “Acidic amino acid” refers to hydrophilic amino acids having a side chain pK value of less than 7, which are typically negatively charged at physiological pH. Acidic amino acids include glutamate (Glu or E), and aspartate (Asp or D).
- Sequence identity is used to evaluate the similarity of two sequences; it is determined by calculating the percent of residues that are the same when the two sequences are aligned for maximum correspondence between residue positions. Any known method may be used to calculate sequence identity; for example, computer software is available to calculate sequence identity. Without wishing to be limiting, sequence identity can be calculated by software such as NCBI BLAST2 service maintained by the Swiss Institute of Bioinformatics (and as found at http://ca.expasy.org/tools/blast/), BLAST-P, Blast-N, or FASTA-N, or any other appropriate software that is known in the art.
- the substantially identical sequences of the present invention may be at least 70%, 80%, 90%, or 95% identical; in another example, the substantially identical sequences may be at least 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical at the amino acid level to sequences described herein. Importantly, the substantially identical sequences retain the activity and specificity of the reference sequence.
- the present invention also encompasses nucleic acids encoding the antigen as described above, as well as vectors comprising the nucleic acid.
- the recombinant bacterium of the present invention may comprise a nucleic acid encoding the antigen as described above, or may comprise a vector (also referred to herein as“plasmid”) comprising such nucleic acid that is fused with the nucleic acid of a translocation domain and optionally the nucleic acid of a chaperone; for example, and without wishing to be limiting in any manner, the vector in which antigen is translocated to the cytosol of infected cells may be a modified pHR plasmid.
- the modified pHR construct uses the type III secretion protein to generate fusion proteins that are transported out of the phagosome and through the host bacterial type III secretion system for direct cytosolic antigen presentation.
- the pHR constructs may comprise sequences encoding a translocation domain and optionally a chaperone protein to aid in proper trafficking of the downstream fusion protein.
- the vector may be a modified pHR-241 plasmid (Russmann et al., 2001); more specifically, the pHR-241 comprising the sequence of SycE-YopE-p60/M45 fusion protein (Russmann et al., 2000) modified to remove the sequence of p60/M45.
- the pHR241 vector is modified to comprise YopE or a fragment of YopE (for example, but not limited to MKISSFISTSLPLPTSVS, SEQ ID NO:2) with the sequence for the SycE and p60/M45 proteins removed.
- YopE or a fragment of YopE
- SEQ ID NO:2 the sequence for the SycE and p60/M45 proteins removed.
- Replacement of the antigenic sequence by appropriate restriction enzymes and subsequent ligation of other antigens would result in development of the desired CD8+ T cell response against said antigens upon vaccination.
- the recombinant bacterium that harbors this plasmid need not be a highly virulent bacterium; for example, attenuated Salmonella is presently shown to be effective at inducing the desired response. The response can be accentuated further by vaccination with higher doses of the attenuated strain.
- the recombinant bacterium as described above may be utilized to impart immunity against other naturally-occurring and virulent bacteria. This may be accomplished by administering an effective amount of the recombinant bacterium of the present invention to a subject, and allowing a CD8 + T cell response to be mounted. Similarly, the recombinant bacterium may be utilized to impart immunity against tumors in a subject, by administering an effective amount of the recombinant bacterium of the present invention to said subject. In both methods, the recombinant bacterium may be administered through intravenous, oral or subcutaneous routes of immunization. This approach avoids the unwanted side-effects of persisting bacteria and undesirable toxicity/inflammation associated with live vaccines.
- the modified bacterium can be administered through the oral route for induction of the desired CD8+ T cell response.
- the recombinant bacterium as described above may also be utilized as a vaccine; the vaccine may protect against other naturally-occurring and virulent bacteria, other bacterial pathogens, viral pathogens, or tumors.
- the antigen is a tumour-antigen
- the tumour-antigen will be translocated to the host cell cytosol, resulting in rapid activation of tumor-specific CD8 + T cells, which will translate to better tumour control by tumor-specific CD8+ T cells.
- the recombinant bacterium described herein may be used as a novel vaccine, wherein a key modification makes the bacterium generate rapid, potent CD8+ T cell response, resulting in self-destruction of the vaccine in vivo, making it highly efficacious, safe and cost-effective.
- the utility of the recombinant bacterium described herein is demonstrated using OVA, TRP-2, and gp-100 as antigens.
- other putative antigens from other pathogens (bacteria, virus) or tumours can be cloned into the recombinant bacterium; these antigens can then be translocated into the host cell cytosol for rapid and potent antigen-presentation using the a translocation domain/chaperone system.
- FIG. 1A shows a schematic of the fusion protein, where OVA is fused to YopE and SycE.
- YopE is a 23 kDa protein comprising a N-terminal secretion domain ( ⁇ 11 aa) and a translocation domain (at least 50 aa); the latter domain provides the binding site for the YopE-specific chaperone (SycE) that is required for YopE-mediated translocation of fused proteins to the cytosol (R).
- SycE is a chaperone necessary for translocation of the fused protein into the cytosol of infected cells through the type III secretion system of ST.
- FIG. 1B A schematic of both ST-OVA-NT and ST-OVA-T constructs and their proposed actions are shown in FIG. 1B .
- Plasmid pHR-OVA was constructed by the modification of the plasmid pHR-241 (Russmann et al., 2001), which contains the sequence of the fusion protein SycE-YopE-p60/M45 (Russmann et al., 2000). In a first step, the genes of p60/M45 were removed by cutting plasmid pHR-241 with BamHl and Kpnl. Then, the pKK-OVA plasmid was purified from the recombinant ST-OVA-NT bacteria by mid prep kit (Invitrogen, US) according to the manufacturer's instructions.
- the OVA gene was PCR-amplified using the plasmid pKK-OVA as a template (forward primer BamHl 5′-CGGGATCCAACTTTCAAACAGCTG-3′ (SEQ ID NO:13) and reverse primer Kpnl 5′-GGGGTACCTTAAGGGGAAACACATC-3′ (SEQ ID NO:14). Subsequently, the OVA gene was inserted between the BamHl-Kpnl sites of the cut pHR-241 palsmid, creating new plasmid pHR-OVA.
- PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C.
- the amplified insert was ligated into the intended vector then sequenced to verify the accuracy of the amplified cDNA.
- the pHR-OVA plasmid was then transfected into the highly virulent ST (strain SL1344). 50 ⁇ L of electrocompetent Salmonella (WT or aroA) were mixed with ⁇ 20 ng plasmid DNA and pulsed in a Bio-Rad micropulser using one pulse of 2.5 kV. Immediately afterwards, 1 mL of SOC recovery medium was added to the bacteria and they were allowed to recover with shaking at 37° C. The bacteria were then plated on LB agar plates with ampicillin for the selection of individual clones.
- ST-OVA-NT and ST-OVA-T constructs of Example 1 were grown and expression and translocation of ovalbumin was evaluated. Pellet and supernatant of ST-OVA-NT and ST-OVA-T growing in liquid cultures were tested for the presence of OVA.
- C57BL/6J mice were injected intravenously with 10 6 ST-OVA-NT or ST-OVA-T reconstituted in 200 microlitres normal saline. Two days later, spleens were obtained from infected mice; spleen cells were isolated and lysed with TRITON X-100 in the presence of protease inhibitor, phenylmethylsulfonyl fluoride. The soluble lysate containing cytosolic proteins was tested for OVA expression by western blotting. Samples were normalized for cell number and were loaded on SDS-10% polyacrylamide gels. SDS-PAGE was performed and proteins were transferred to membranes, which were then blocked with 5% skim milk powder in PBS-TWEEN.
- OVA expression was detected using a 1/10,000 dilution of polyclonal anti-OVA antibody (Sigma-Aldrich), followed by incubation with HRP-conjugated goat anti-rabbit Ab ( 1/5,000 dilution in PBS-TWEEN) from Roche Applied Science. Immuno-reactive bands were detected with enhanced chemiluminescence substrate (Roche Applied Bioscience). Results show that OVA-expression by ST-OVA-NT and ST-OVA-T (from ⁇ 5 ⁇ 10 6 ) in the bacterial pellets was similar ( FIG. 1C ). However, OVA could only be detected in the supernatant of ST-OVA-T cultures. Expression of OVA was detectable in the cytosol of spleen cells from mice infected with ST-OVA-T- but not ST-OVA-NT ( FIG. 1C ).
- IC-21 macrophages H-2 b
- gentamicin 50 ⁇ g/ml
- ST-OVA-T ST-OVA-T
- IC-21 macrophages (H-2 b ) cells (10 5 /well) were infected with different MOI of ST (Albaghdadi et al., 2009), ST-OVA-NT (Example 1), or ST-OVA-T (Example 1) for 30 min. Extracellular bacteria were removed after incubation in medium containing gentamicin (50 ⁇ g/ml). At 2 h, cells were cultured in media containing lower levels of gentamicin (10 ⁇ g/ml) and incubated with CFSE-labelled OT-1 (CD45.1 + 45.2 ⁇ ) TCR transgenic cells (10 6 /well). After 4 days of culture, cells were harvested, stained with anti-CD45.1 and anti-CD8 antibodies, and the reduction in CFSE intensity of OT-1 CD8 + T cells was evaluated by flow cytometry.
- B6129F1 mice were infected with the recombinant bacteria of Example 1, followed by adoptive transfer of CFSE labelled OT-1 cells.
- B6.129F1 mice were used because B6 parents are highly susceptible and die within the first week of infection (Albaghdadi et al., 2009). Briefly, B6129F1 mice were generated in house by mating 129 ⁇ 1 SvJ female mice with C57BL/6J male mice; mice were obtained from The Jackson Laboratory and were maintained at the Institute for Biological Sciences (National Research Council of Canada, Ottawa, Canada) in accordance with the guidelines of the Canadian Council on Animal Care.
- CFSE-labelled OT-1 cells were injected (5 ⁇ 10 6 , iv).
- spleens were isolated from recipient mice and spleen cells were stained with OVA-tetramer and anti-CD8 antibody. Reduction in the expression of CFSE intensity was evaluated by flow cytometry, as described above.
- results are shown in FIGS. 3B and 3C ; results represent the mean of three mice ⁇ SD per group, and are representative of two-three independent experiments.
- the majority of transferred OT-1 cells displayed reduced expression of CFSE in mice infected with ST-OVA-T ( FIG. 3B ).
- OT-1 cells in ST-OVA-NT-infected mice maintained high levels of CFSE expression.
- ST-OVA-NT infected mice displayed muted and delayed activation of CFSE-labelled OT-1 cells ( FIG. 3C ).
- the massive antigen-presentation that was induced early on in ST-OVA-T infected mice was subsequently reduced to baseline levels as the pathogen was cleared.
- B6.129F1 mice were infected (10 3 , iv) with ST-OVA-T or ST-OVA-NT without any adoptive transfer of OT-1 cells. At various time intervals, the numbers of spleen cells, spleen size and bacterial burden were evaluated. OVA-specific CD8+ T cell response was enumerated by Flow cytometry. Briefly, aliquots of spleen cells (5 ⁇ 10 6 ) were incubated in 80 ⁇ l of PBS plus 1% BSA (PBS-BSA) with anti-CD16/32 at 4° C.
- PBS-BSA BSA
- H-2K b OVA 257-264 tetramer-PE (Beckman Coulter, US) and various antibodies (anti-CD8 PerCP-Cy5, anti-CD62L APC-Cy7, and anti-CD127 (PE-Cy7) for 30 min. All antibodies were obtained from BD Biosciences. Cells were washed with PBS, fixed in 0.5% formaldehyde and acquired on a BD Biosciences FACSCanto analyzer.
- results are shown in FIG. 4 ; these results represent the mean of three to five mice ⁇ SD per group and are representative of three independent experiments.
- Infection of mice with ST-OVA-T resulted in the development of a rapid and potent OVA-specific CD8 + T cell response as evaluated by staining with OVA-tetramers ( FIG. 4D, 4E ; FIG. 5A ); these mice displayed reduced spleen cell numbers and size ( FIG. 4A, 4B ).
- similar bacterial burdens were noted in mice that received ST-OVA-T or ST-OVA-NT ( FIG. 4C ).
- the burden of ST-OVA-T were enormously controlled which was reduced to non-detectable levels by day 30.
- FIG. 5A shows the OVA-tetramer profile in the spleens of infected mice, and the expression (MFI) of CD62L ( FIG. 5B, 5D ) and CD127 ( FIG. 5C, 5D ) on OVA-tetramer + CD8 + T cells.
- MFI expression of CD62L
- FIG. 5C, 5D OVA-tetramer + CD8 + T cells.
- OVA-specific CD8 + T cells induced against ST-OVA-T displayed rapid activation (CD62L down-regulation) and rapid progression to the memory state (CD127 up-regulation) ( FIG. 5B-D ).
- C57BL/6J mice were infected (10 3 , iv) with ST-OVA-T or ST-OVA-NT. At different time points (day 1, 3, 5, 7 and 14) after infection, spleens were removed and the bacterial burdens were enumerated. Spleen cells were stained with OVA-tetramers and antibodies against CD8, CD62L and CD127. The percentage and numbers of OVA-specific CD8 + T cells were determined, as was the expression of CD62L versus CD127 on OVA-tetramer + CD8 + T cells.
- Results are shown in FIG. 6 and represent the mean of three to four mice ⁇ SD per group; results are representative of two independent experiments.
- days 1 and 3 similar bacterial burdens were noted in ST-OVA-NT- and ST-OIVA-T-infected groups ( FIG. 6A ).
- the burden in ST-OVA-T-infected mice was rapidly controlled and became undetectable after day 14.
- Abridgment of bacterial burden in ST-OVA-T-infected mice correlated to the early emergence of potent OVA-specific CD8 + T cell response, as detected by OVA-tetramer staining ( FIG. 6B-C ) that peaked at day 7.
- FIG. 7 shows results of phenotypic analysis of OVA-specific CD8 + T cells induced against ST-OVA-T versus ST-OVA-NT. Similar to the profile in resistant mice, OVA-specific CD8 + T cells induced against ST-OVA-T in susceptible mice displayed rapid down-regulation of CD62L and rapid transition to the memory phenotype (increased CD127 up-regulation; FIG. 7 ).
- Example 6 While the data of Example 6 indicated that rapid emergence of functional CD8 + T cells by antigenic translocation can control ST burden rapidly, it was still correlative.
- C57BL/6J mice were treated with anti-CD8 or anti-CD4 antibody or isotype control then infected with ST-OVA-T to eliminate those cells specifically.
- C57BL/6J mice were treated with (100 ⁇ g/injection) anti-CD4 (clone GK1.5), anti-CD8 (clone 2.43), or Rat IgG isotype antibodies on days ⁇ 3, 0 and 3 after infection with 10 3 ST-OVA-T.
- MHC-I deficient mice lack CD8 + T cells they should be susceptible to infection. Twenty days after infection, MHC-I deficient mice were moribund, displaying very high bacterial loads ( FIG. 8B ) whereas control mice had undetectable burden, and MHC class II-deficient hosts (lacking CD4 + T cells) showed only a minor effect. MHC-I deficient mice were sick due to high bacterial loads, while MHC-II-deficient and WT mice were healthy. Taken together, these results indicate that antigenic translocation to cytosol in the context of ST infection results in a rapid emergence of a potent CD8 + T cell response which is sufficient to control the burden.
- mice were infected with 10 3 (virulent) wild type (WT; SL1344)) or 10 5 attenuated (avirulent; ⁇ aroA) ST-OVA expressing non-translocated or non-translocated OVA.
- 10 3 (virulent) wild type (WT; SL1344) or 10 5 attenuated (avirulent; ⁇ aroA) ST-OVA expressing non-translocated or non-translocated OVA.
- spleens and peripheral blood were collected and the relative change in the numbers of OVA-specific CD8 + T cells enumerated after staining with OVA-tetramers and anti-CD8 antibodies as described in Example 5.
- Results in FIG. 9 represent the mean of five mice ⁇ SD per group. Translocation of OVA by avirulent ST also resulted in rapid and profound induction of OVA-specific CD8 + T cell response in the spleen ( FIG. 9A ) and peripheral blood ( FIG. 9B ). Thus, these results indicate that antigenic translocation works equally well for virulent and avirulent bacteria.
- mice C57BL/6J mice were infected with 10 3 ST-OVA-T; non-infected (na ⁇ ve) mice served as controls.
- mice On day 60, mice were challenged subcutaneously in the lower dorsal region with 10 6 B16 melanoma cells carrying the OVA gene (B16-OVA). Survival of mice was measured subsequently.
- prophylactic vaccination with ST-OVA-T resulted in potent protection against tumour challenge. Protection in a therapeutic model, where mice were first challenged with tumours and then vaccinated with immunogens, was also tested.
- B6.129F1 mice were challenged first with 10 6 B16-OVA tumour cells subcutaneously in the lower dorsal region.
- mice were vaccinated with ST-OVA-NT or ST-OVA-T.
- Non-infected mice served as negative controls and LM-OVA infected mice served as positive controls.
- survival of mice was monitored.
- Mice receiving ST-OVA-T displayed the best protection against B16 melanoma cells ( FIG. 10B ). Protection induced by ST-OVA-T was far greater than that induced by ST-OVA-NT and LM-OVA. Results represent the mean of five mice ⁇ SD per group.
- OVA immunodominant antigen
- tumour-antigen (Trp-2) (Schumacher and Restifo, 2009) was cloned into the WT or aroA mutant of ST, which translocates antigen to the cytosol.
- PCR was done using pCDNA3-Trp2 as template using the following primers:
- the PCR product and pHR-OVA were digested with BamHl and Kpnl and ligated.
- PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C.
- the amplified insert was ligated into the intended vector, then sequenced to verify the accuracy of the amplified cDNA.
- the PCR product was digested with BgIII and Kpnl; pHR-241 was digested with BamHl and Kpnl and the digested products were ligated.
- pHR-Trp2 plasmid was then transfected into the highly virulent ST (SL1344) or aroA mutant of ST.
- 50 ⁇ L of electrocompetent Salmonella (WT or aroA) were mixed with ⁇ 20 ng plasmid DNA and pulsed in a Bio-Rad micropulser using one pulse of 2.5 kV.
- 1 mL of SOC recovery medium was added to the bacteria and they were allowed to recover shaking at 37° C. The bacteria were then plated on LB agar plates with ampicillin for the selection of individual clones.
- the PCR product was digested with BgIII and Kpnl; pHR-241 was digested with BamHl and Kpnl and the digested products were ligated.
- Infection of B6.129F1 mice with these recombinant nucleic acids resulted in the induction of CD8+ T cell response against Trp-2 ( FIG. 11A ). This was associated with accelerated control of the bacterium ( FIG. 11B ,C).
- infection of mice with the gp100 expressing aroA-ST resulted in accelerated control of the bacterium ( FIG. 12A ) and induction of a better CD8+ T cell response against gp100 ( FIG. 12B ).
- the immunodominant epitope recognized to stimulate a CD8 + T cell response from LCMV nucleoprotein (NP) in C57B1/6 mice was also used as an antigen and cloned into ST, and its effect on T cell response in mice was evaluated.
- LCMV-NP was encoded over amino acids 396-404 (FQPQNGQFI) of the protein (Basler et al., 2004).
- cDNA encoding amino acids 288-463 of the NP protein was cloned into plasmid pKK to generate pKK-NP ( FIG. 13 ), using PCT methods as described in Example 1 and 11. Again, DH5a clones were selected using ampicillin. In this case, Ncol and HindIII restriction sites were added to the oligonucleotides used for amplification of the insert sequence.
- the oligonucleotide sequences used for the cDNA amplification were:
- the final insert in the pKK plasmid was truncated prior to the end of the amplified insert due to the presence of an internal HindIII restriction site, ending at codon 461. After confirmation of the sequence, this plasmid was also transferred into ST wild type and ST ⁇ Aro using a standard electroporation protocol (as described below and in Examples 1 and 11).
- cDNA encoding amino acids 288-461 of the NP protein was similarly cloned into the plasmid, pKK, to generate pKK-NP ( FIG. 13 ). Again, DH5a clones were selected using ampicillin. In this case, Ncol and HindIII restriction sites were added to the oligonucleotides used for amplification of the insert sequence.
- the oligonucleotide sequences used for the cDNA amplification are:
- the final insert in the pKK plasmid was truncated prior to the end of the amplified insert due to the presence of an internal HindIII restriction site, ending at codon 461. After confirmation of the sequence, this plasmid was also transferred into ST wild type and ST ⁇ Aro using a standard electroporation protocol. Briefly, 50 ⁇ L of electrocompetent Salmonella (WT or aroA) were mixed with ⁇ 20 ng plasmid DNA and pulsed in a Bio-Rad micropulser using one pulse of 2.5 kV. Immediately afterwards, 1 mL of SOC recovery medium was added to the bacteria and they were allowed to recover shaking at 37° C.
- WT or aroA electrocompetent Salmonella
- the bacteria were then plated on LB agar plates with ampicillin for the selection of individual clones.
- PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C.
- the amplified insert was ligated into the intended vector then sequenced to verify the accuracy of the amplified cDNA.
- mice were infected intravenously with 10 3 recombinant ST expressing NP. Both virulent ( FIG. 13B ,C) and avirulent ( FIG. 13D ) ST induced profound NP-specific CD8+ T cell response when NP was translocated to the cytosol. Furthermore, antigenic translocation resulted in decreased bacterial burden ( FIG. 13E ) and control of vaccine induced inflammation ( FIG. 13F ).
- Truncated YopE as a Means to Induce Potent CD8+ T Cell Response
- the PCR product and pHR-OVA were digested with EcoRl and BamHl and ligated.
- PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C.
- the amplified insert was ligated into the intended vector, then sequenced to verify the accuracy of the amplified cDNA.
- S. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells.
- the Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1.
- Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291, 238-239.
- Yersinia enterocolitica-mediated translocation of defined fusion proteins to the cytosol of mammalian cells results in peptide-specific MHC class I-restricted antigen presentation.
- Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med. 9, 1039-1046. Schumacher, T. N. and Restifo, N. P.
- Salmonella entry into host cells the work in concert of type III secreted effector proteins. Microbes. Infect. 3, 1293-1298. Zhu, X., Zhou, P., Cai, J., Yang, G., Liang, S., and Ren, D. (2010). Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma. Cancer Sci. 101, 2621-2628.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
Abstract
The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type Ill secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided.
Description
- This application is a Continuation, and claims priority under 35 U.S.C. §120 to, U.S. application Ser. No. 14/516,090 filed Oct. 16, 2014, which is a Continuation of U.S. application Ser. No. 13/811,690 filed Jan. 23, 2013, which is a national stage entry from International Patent Application No. PCT/CA2011/00848 filed Jul. 28, 2011, which in turn claims priority to U.S. Provisional Patent Application No. 61/368,346 filed Jul. 28, 2010, each of which is incorporated herein by reference. Also, the Sequence Listing filed electronically herewith is hereby incorporated by reference (File name: 2016-12-05T_1036-0014C_Seq_List; File size: 43 KB; Date recorded: Dec. 5, 2016).
- The present invention relates to recombinant bacterium and uses thereof. More specifically, the invention relates to recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof.
- Various vaccine vectors or adjuvants that induce potent T cell responses are known in the art (Kaufmann and Hess, 1997). However, very few vaccine vectors exist that induce rapid and potent memory CD8+ cytolytic T cell responses, and that are safe and cost-effective (Raupach and Kaufmann, 2001). Unlike other T cells, CD8+ T cells uniquely provide immune-surveillance to the entire body because they recognize targets in the context of MHC class I molecules, which are present in every cell (Bevan, 1995). Furthermore, CD8+ T cells can eliminate infected cells or tumour cells rapidly. Thus, the induction of specific, potent CD8+ T cells is highly desirable for diseases that are caused by intracellular pathogens and tumours.
- Intracellular pathogens induce CD8+ T cell responses; however, the responses are either highly attenuated or the organism itself is highly toxic. Generally, rapid proliferation of pathogens is countered by rapid presentation of antigen to CD8+ T cells within the first few days of infection and activated CD8+ T cells undergo profound expansion (>1000-fold) within the first week of infection, which results in resolution of infection (Kaech and Ahmed, 2001). Similarly, CD8+ T cells play a key role in mediating immune-surveillance against tumours (Smyth et al., 2000). While antibodies and helper T cells mainly promote clearance of extracelluar pathogens (Kaech et al., 2002), CD8+ T cells play a principal role in controlling intracellular pathogens and tumours. Thus, rapid induction of memory CD8+ T cells is essential for developing vaccines against tumours or intracellular pathogens.
- While the CD8+ T cells play a key role against various diseases, their induction is highly tedious. Antigenic proteins injected into hosts in the absence or presence of adjuvants does not lead to the induction of CD8+ T cells (Moore et al., 1988). This is mainly because extracelluar proteins do not gain access to the cytoplasm (cytosol) of antigen-presenting cells (APC) (Rock, 1996). Rather, these extracellular proteins or vaccines are trafficked through specialized intracellular vesicles called phagosomes, which leads to the activation of helper T cells to aid antibody production. For induction of CD8+ T cell responses, the pathogen or the vaccine has to reside within the cytosol of an antigen-presenting cell (Bahjat et al., 2006).
- Alternative routes of cross-presentation of non-cytosolic antigens to T cells have been suggested (Schaible et al., 2003; Houde et al., 2003; Yrlid and Wick, 2000), however the efficiency of these pathways in controlling pathogens isn't clear (Freigang et al., 2003). Dendritic cells may pick up antigen from dying APCs and present it to CD8+ T cells (Albert et al., 1998). Salmonella enterica serovar Typhimurium (ST) induces rapid death of macrophages and dendritic cells (Hersh et al., 1999; van der Velden et al., 2000) and it has been shown that cross-presentation of ST antigens occurs through dendritic cells (Yrlid and Wick, 2000). Phagosomes have themselves been considered to be competent at promoting cross-presentation (Houde et al., 2003). However, these mechanisms are of little protective value since rapid pathogen elimination is not observed. Cells that are cross-presenting ST antigens don't appear to serve as good targets for CD8+ T cells to mediate their function. Thus, target cell accessibility seems to be the critical difference between direct and cross-presentation.
- Subunit vaccines that consist of purified proteins admixed with adjuvants typically do not induce CD8+ T cell response due to residence of these entities within phagosomes of cells (Bahjat et al., 2006). However, some adjuvants induce CD8+ T cell responses most likely by the cross-presentation pathway (Krishnan et al., 2000). Subunit vaccines are difficult to mass-produce and are faced with numerous technical difficulties including batch to batch variability, quantitation of the antigen-adjuvant ratio, and extensively laborious procedures. To avoid this problem, live vaccines are preferred. However, live vaccines can be either over- or under-attenuated and it is difficult to find the right balance (Raupach and Kaufmann, 2001).
- Typically, viral infections (such as Lyphochoriomeningitis virus, LCMV) lead to potent activation of CD8+ T cell responses due to their replication within the cytosol of infected cells (Kaech et al., 2002; Murali-Krishna et al., 1998). However, it is difficult to justify the use of viral vectors as a live vaccine due to the lack of availability of reagents to control the virus, particularly in immunocompromised hosts. Live bacteria can be considered as an alternative option for vaccine development since antibiotics can be used in case they are not controlled by the host. However, extracellular bacteria do not gain access to the cytosol of infected cells, hence fail to induce CD8+ T cell response (Bevan, 1995). On the other hand, intracellular bacteria induce CD8+ T cell response, albeit poor, despite residing within the phagosomes of infected cells, perhaps by cross-presentation (Kaufmann, 1993)—the caveat being that intracellular bacteria (e.g., Salmonella, Mycobacteria, Leishmania) that reside within the phagosomes of infected cells induce a chronic infection, implying that CD8+ T cells fail to eradicate them from the host (Kaufmann, 1993; Hess and Kaufmann, 1993).
- There remains a need in the art for a safe, cost-effective method to induce rapid and potent memory CD8+cytolytic T cell responses.
- The present invention relates to recombinant bacterium and uses thereof. More specifically, the invention relates to recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof.
- The present invention provides a recombinant bacterium, comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell. The bacterium may be Salmonella, Mycobacteria, Brucella, or Leishmania. In one example, the recombinant bacterium may be Salmonella.
- The antigen expressed by the recombinant bacteria as just described may be a viral antigen, a bacterial antigen, or a tumour antigen. The antigen may be the nucleoprotein of LCMV, tyrosinase related protein 2 (TRP-2), MART-1, melanoma associated antigen 1 (MAGE1), gp100, or Her-2/neu or other viral or bacterial antigens.
- The nucleic acid encoding the antigen may encode a fusion protein comprising the antigen and a translocation domain from a type III secretion system. For example, the translocation domain may be YopE, SopE, SptP, or a fragment thereof.; in one specific example, the chaperone may be SycE or a fragment thereof (such as, but not limited to MKISSFISTSLPLPTSVS, SEQ ID NO:2). The fusion protein may optionally further comprise a chaperone. The chaperone may be derived from a type III secretion system. For example, the chaperone may be SycE or HSP70.
- The nucleic acid may be comprised in a vector. The vector may be a pHR vector; in a specific example, the vector may be a modified pHR-241 vector. In the modified pHR-241 vector, the vector may be modified to remove the sequence of p60/M45, may be optionally further modified to remove the sequence of SycE.
- Specific, non-limiting examples of fusion proteins encompassed by the present invention are those of SEQ ID NO:7 to SEQ ID NO:12.
- The present invention also provides a method of imparting immunity against naturally-occurring bacterium in a subject, the method comprising administering the recombinant bacterium described above to said subject.
- The present invention further provides a method of imparting immunity against tumours in a subject, the method comprising administering the recombinant bacterium described above to said subject. The recombinant bacterium may be administered by intravenous, oral, or subcutaneous routes of immunization.
- The present invention also encompasses a use of the recombinant bacterium described herein as a vaccine.
- Previously, it was known that pathogen-specific CD8+ T cells remain ineffective as long as the pathogen remained in the phagosome. For example, when conventional memory CD8+ T cells against a given antigen were adoptively transferred to naïve hosts, they failed to respond rapidly in response to the same antigen expressed by ST infection (Luu et al., 2006). Presently, a recombinant ST that injects an antigen directly into the host cytosol has been developed. This results in profound CD8+ T cell activation and consequent elimination of ST. It is also shown that when CD8+ T cells are engaged in this manner, they undergo profound expansion which results in massive pathogen and tumour control as well as abridgment of pathogen chronicity. For example, as is evident in present
FIG. 3E , the numbers of OVA-specific CD8+ T cells were similar atday 60 in ST-OVA-T versus ST-OVA-NT groups, but the burden was controlled only in the ST-OVA-T infected group, reiterating the notion that antigenic accessibility is the key to CD8+ T cell functionality. This strategy works even with attenuated strains of Salmonella. - Notwithstanding the numerous genes that pathogens such as ST employ for virulence and chronicity (Jones and Falkow, 1996; Kaufmann et al., 2001), the present data provide novel insights into the incapacity of the immune system to efficiently control the bacterium, as well as reveal the power of the acquired immune system, wherein engagement of potent antigen-presentation early on can be sufficient to control an otherwise uncontrollable bacterium. The present results provide compelling evidence that modulation of the cell biology of antigen trafficking is a key avenue that is employed by various pathogens for immune evasion. Thus, a novel vaccine vector (Salmonella) is presently provided, wherein a key modification makes the bacterium generate rapid, potent CD8+ T cell response, resulting in self-destruction of the vaccine in vivo, making it highly efficacious, safe and cost-effective at the same time.
- The use of OVA as an antigen is described herein as a proof of principle. Using a similar approach, other putative antigens from other pathogens (bacteria, virus) or tumours can be cloned into ST and these antigens can be translocated into the host cell cytosol for rapid and potent antigen-presentation using the YopE/SycE system. When a tumour-antigen is cloned into ST using the YopE/SycE system, potent and rapid anti-tumour CD8+ T cell response is generated which consequently results in rapid destruction of the bacterium.
- Additional aspects and advantages of the present invention will be apparent in view of the following description. The detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only, as various changes and modifications within the scope of the invention will become apparent to those skilled in the art in light of the teachings of this invention.
- These and other features of the invention will now be described by way of example, with reference to the appended drawings, wherein:
-
FIG. 1A shows a schematic of the fusion protein constructed, where an antigen (OVA) is fused to YopE, which is then incorporated into the plasmid pHR241 containing the SycE chaperone.FIG. 1B shows a schematic of the antigen (OVA) translocation into the cytosol for ST-OVA-T, and the lack thereof for ST-OVA-NT. Ag: antigen; OVA: ovalbumin; ST: Salmonella Typhimurium.FIG. 1C shows expression of OVA (by western blot) in the bacterial pellet, supernatant, and the cytosol of spleen cells of mice infected for 24 h with ST-OVA-NT and ST-OVA-T. -
FIG. 2A shows a graph representing the doubling times of the ST-OVA-NT (closed circles) and ST-OVA-T (open circles) bacteria in liquid culture, based on the measurement of OD at 600 nm. Based on these values, the bacteria were found to be similar.FIG. 2B is a graph showing the ST burden in IC-21 macrophages (H-2b) infected with ST-OVA-NT or ST-OVA-T (multiplicity of infection, MOI=10). No statistically significant difference was detected in the ability of ST-OVA-NT or ST-OVA-T to infect and replicate within macrophages (p>0.05). Results are representative of three independent experiments. -
FIG. 3A shows flow cytometry results of in vitro infection of IC-21 macrophages (H-2b) with recombinant bacteria (ST-OVA-NT, ST-OVA-T, or ST). The reduction in CFSE intensity of OT-1 CD8+ T cells indicated that infection of macrophages with ST or ST-OVA-NT did not result in any detectable proliferation of OT-1 cells, and thus, a lack of antigen-presentation. Infection with ST-OVA-T resulted in strong dilution of CFSE expression, which is indicative of rapid and potent antigen-presentation.FIG. 3B shows flow cytometry results of in vivo infection of B6.129F1 mice infected with ST-OVA-NT or ST-OVA-T (Day 5). In ST-OVA-T-infected mice, the majority of transferred OT-1 cells displayed reduced expression of CFSE while OT-1 cells in ST-OVA-NT-infected mice maintained high levels of CFSE expression. Results represent the mean of three mice ±SD per group, and are representative of 2-3 independent experiments.FIG. 3C is a graphical representation of the kinetic evaluation of in vivo antigen-presentation. ST-OVA-NT infected mice displayed muted and delayed activation of CFSE-labelled OT-1 cells. ST-OVA-NT (closed circles); ST-OVA-T (open circles). -
FIG. 4A shows the numbers of spleen cells, spleen size at Day 14 (FIG. 4B ) and bacterial burden (FIG. 4C ) in resistant (B6.129F1) mice infected with ST-OVA-T or ST-OVA-NT, as well as the percentage (FIG. 4D ) and numbers (FIG. 4E ) of OVA-specific CD8+ T cells in the spleen. Results represent the mean of three to five mice ±SD per group and are representative of three independent experiments. ST-OVA-NT (closed circles); ST-OVA-T (open circles). -
FIG. 5A shows the OVA-tetramer profile in the spleens of ST-OVA-T- or ST-OVA-NT-infected resistant (B6.129F1) mice atDay 7. The expression of CD62L (FIG. 5B, 5D ) and CD127 (FIG. 5C, 5D ) on OVA-tetramer+CD8+ T cells is also shown. Results are representative of three independent experiments. These results indicate early generation of memory CD8+ T cells in mice infected with ST-OVA-T. ST-OVA-NT (closed circles); ST-OVA-T (open circles). -
FIG. 6A shows the bacterial burdens in spleen cells of susceptible (C57BL/6J) mice infected with ST-OVA-T or ST-OVA-NT, along with the percentage (FIG. 6B ) and numbers (FIG. 6C ) of OVA-specific CD8+ T cells, as well as the frequency of OVA-specific CD8+ T cells evaluated by ELISPOT assay (FIG. 6D ). The specific killing of OVA-pulsed targets in naïve mice exposed to OVA-pulsed and control spleen cells is shown ifFIG. 6E and F, indicating that ST-OVA-T infection results in rapid induction of antigen-specific CD8+ T cells that can efficiently kill antigen-bearing target cells. Results represent the mean of three to four mice ±SD per group, and two independent experiments. ST-OVA-NT (closed circles); ST-OVA-T (open circles). -
FIG. 7A shows the OVA-tetramer profile in the spleens of susceptible (C57BL/6J) mice infected with ST-OVA-T or ST-OVA-NT atDay 7.FIG. 7B shows the expression of CD62L versus CD127 on splenic OVA-tetramer+CD8+ T cells in the ST-OVA-T versus ST-OVA-NT infected mice. CD8+ T cells generated with ST-OVA-T infection express high levels of CD127 and CD62L (memory markers). Results are representative of three independent experiments. -
FIG. 8A shows the bacterial burden in spleens of C57BL/6J mice treated with anti-CD4 (clone GK1.5), anti-CD8 (clone 2.43) or Rat IgG isotype antibodies following infection with ST-OVA-T. Results represent the mean of three to four mice ±SD per group. Anti-CD4 and anti-CD8 antibody treatment resulted in near complete elimination of CD4 and CD8+ T cells respectively.FIG. 8B shows the bacterial burden in spleens of WT, MHC-I- or MHC-II-deficient mice following infection with ST-OVA-T. These results indicate that the control of bacterial burden in ST-OVA-T infected mice is mediate exclusively by CD8+ T cells. Results represent the mean of five mice ±SD per group. -
FIG. 9A shows the relative numbers of OVA-specific CD8+ T cells in the spleen and peripheral blood (FIG. 9B ) of B6.129F1 mice infected with wild type (WT) or attenuated (ΔaroA) ST-OVA expressing non-translocated (NT) or translocated (T) OVA. Results represent the mean of five mice ±SD per group. Results indicate that even attenuated strain of ST can induce potent and rapid CD8 T cell response when antigen is translocated to the cytosol of infected cells. WT-OVA-NT (closed circles); WT-OVA T (open circles); AroA-OVA-NT (closed inverted triangles); AroA-OVA-T (open inverted triangles). -
FIG. 10A is a graphical representation of the results of prophylactic vaccination with ST-OVA-T in C57BL/6J mice followed by subcutaneous challenge with B16-OVA tumor cells. This protocol resulted in potent protection against tumor challenge. Non-infected (closed circles); ST-OVA-T (open squares).FIG. 10B shows a graph of results of therapeutic vaccination with ST-OVA-T in C57BL/6J mice after subcutaneous challenge with B16-OVA tumor cells. Mice receiving ST-OVA-T displayed the best protection against B16 melanoma cells. Protection induced by ST-OVA-T was far greater than that induced by ST-OVA-NT and the another recombinant bacterium, Listeria expressing OVA (LM-OVA). Results represent the mean of five mice ±SD per group. Non-infected (full circles); ST-OVA-T (open squares); ST-OVA-NT (closed triangles); LM-OVA (open diamonds). -
FIG. 11A shows the frequency of CD8+ T cells against a tumour antigen (Trp-2) in the spleens of mice infected with wild-type (WT) or attenuated (aroA) ST-Trp2-T onDay 7.FIG. 11B shows the bacterial burden in the spleens of mice at various time intervals post-infection with WT ST-Trp2-T (open squares) or ST-Trp2-NT (closed circles).FIG. 11C shows the bacterial burden in the spleens of mice infected with aroA mutant of ST-Trp2-T (open squares) or NT (closed circles). -
FIG. 12A shows the bacterial burden in the spleens of mice infected with translocated or non-translocated aroA-ST expressing another tumour antigen (gp100). aroA-gp100-T (open squares) or aroA-gp100-NT (closed circles).FIG. 12 B shows the numbers of gp100-tetramer+CD8+ T cells in the spleens of infected mice at various time intervals. aroA-ST-gp100-T (open squares); aroA-ST-gp100-NT (closed circles). -
FIG. 13A shows the schematic of the fusion constructs.FIG. 13B shows the frequency of NP-specific CD8+ T cells in mice infected with ST-NP-T or ST-NP-NT atday 7 post-infection.FIG. 13C shows the in vivo cytolytic activity of NP-specific CD8+ T cells on NP-pulsed target cells atday 7 post-infection. Cytolytic activity was evaluated after transferring naïve spleen cells (pulsed with media or NP peptide) into infected mice atday 7 and evaluated the killing of peptide-pulsed targets at 24 h post-transfer.FIG. 13D shows the frequency of NP-specific CD8+ T cells in mice infected with aroA-NP-T (black bars) or aroA-NP-NT (white bars).FIG. 13E shows the bacterial burden in the spleens at various time intervals. aroA-NP-T (open squares) or aroA-NP-NT (closed circles)FIG. 13F shows the influence of antigenic translocation on the induction of inflammation in the spleen. aroA-NP-T (open squares); aroA-NP-NT (closed circles). -
FIGS. 14A-14E shows that truncated YopE is equally effective at inducing CD8+ T cell response.FIG. 14A shows the schematic representation of the full length (upper panel) and the truncated YopE (lower panel).FIG. 14B shows the OVA-specific CD8+ T cell response in the spleens of mice infected with full YopE or truncated YopE.FIG. 14C shows that both the full length and truncated YopE induce the rapid generation of OVA-specific CD8+ T cells expressing memory marker (CD127).FIG. 14D shows the inflammation induced (numbers of spleen cells) in mice infected with full length or truncated YopE.FIG. 14E shows the bacterial burden in the spleens of mice infected with full length or truncated YopE. ST-OVA-NT (closed circles); ST-OVA-T (open circles); ST-OVA-tYopE (closed triangles). - The present invention relates to recombinant bacterium and uses thereof. More specifically, the invention relates to recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof.
- The present invention provides a recombinant bacterium, comprising a nucleic acid encoding an antigen that is translocated to the cytosol of the host organism.
- The bacterium may be any virulent or attenuated bacterium that resides in the phagosome of macrophages and/or dendritic cells and induces poor T cell activation. Such a bacterium may be, but is not limited to Salmonella, Mycobacteria, Brucella, Leishmania, and the like, which are all intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation, hence causing diseases that are not controlled by the immune system.
- In one example, the virulent or attenuated bacterium may be Salmonella. Any suitable strain of Salmonella known in the art may be used; for example, and without wishing to be limiting in any manner, the virulent or attenuated bacterium may be Salmonella enterica, serovar Typhimurium (ST). ST is a highly virulent pathogen that induces gastroenteritis in humans, and typhoid-like disease in mice (Jones and Falkow, 1996). In susceptible C57BL/6J mice, which lack natural resistance-associated macrophage proteins (NRAMP), ST (strain SL1344) induces a systemic lethal infection even at doses as low as (102) (iv), and all mice die within 7 days of infection (Albaghdadi et al., 2009). In contrast, ST induces a chronic but non-lethal infection in resistant 129SvJ mice (which express NRAMP). F1 hybrids between susceptible and resistant mice (B6.129F1) also harbour a chronic, non fatal, infection (Luu et al., 2006). Genes that are involved in Salmonella invasion of epithelial cells are clustered at the Salmonella pathogenicity island-1 loci (SPI-1) (Bliska et al., 1993; Zhou and Galan, 2001; Galan and Curtiss, Ill, 1989; Hardt et al., 1998). They encode several factors, including a type III secretion system (TTSS) apparatus that exports specific proteins (effectors) into the host cell. Two major virulence loci allow Salmonella to survive inside cells (Jones and Falkow, 1996). The two-component regulatory system phoP/phoQ, which controls >40 genes (Groisman et al., 1989; Miller et al., 1989), is involved in intracellular survival (Garvis et al., 2001). Another pathogenicity island (SPI-2) encodes a second TTSS, mediates resistance to intracellular killing, and is key to virulence (Hensel et al., 1995; Shea et al., 1996).
- The CD8+ T cell response against ST is delayed, which fails to control the bacterium leading to a chronic infection (Albaghdadi et al., 2009). aroA mutant of ST was developed as a vaccine against Salmonella (Hoiseth and Stocker, 1981), which induces minimal inflammation and poor immunogenicity (Albaghdadi et al., 2009; Dudani et al., 2008). The virulent or attenuated bacterium of the present invention may be the aroA mutant of ST, comprising a vaccine vector modified such that the bacterium resides in the phagosome of infected cells, but translocates antigen to the cytosol. This modification allows rapid induction of CD8+ T cells; without wishing to be bound by theory, this may lead to the self-destruction of the vaccine. Phagosomal localization is considered a major impediment to T cell activation, and the antigenic translocation strategy described herein can be used for other intracellular bacterial vaccine vectors, including Mycobacteria, Brucella or Leishmania.
- By the term “recombinant” it is meant that the bacterium has been genetically altered or engineered; such genetic engineering may be the inclusion of a recombinant (or artificial) nucleic acid or vector (comprising a nucleic acid) encoding a foreign protein that is an antigen.
- The antigen may be any suitable protein or fragment thereof that is processed and presented efficiently by dendritic cells and/or macrophages resulting in efficient T cell activation. Without wishing to be limiting in any manner, the antigen or fragment thereof may be a nascent protein, a bacterial antigen, viral antigen, or a tumour antigen. For example, the antigen may be, but is not limited to tyrosinase related protein 2 (TRP-2), MART-1, melanoma associated antigen 1 (MAGE1), gp100, Her-2/neu or other proteins or fragments thereof known in the art. Other proteins may include, but are not limited to ovalbumin, hen egg lysozyme, and myelin basic protein, nuclear protein of LCMV. In a specific, non-limiting example, the antigens may be ovalbumin, TRP-2, gp-100, LCMV-NP, or fragments thereof.
- Upon infection, the antigen is translocated into the cytosol of the host cell (for example macrophages and/or dendritic cells). The antigen may naturally translocate to the cytosol, or may be a recombinant protein engineered to do so. Thus, the antigen may be comprised in a fusion protein that further comprises a translocation domain from a type III secretion system; optionally, the fusion protein may further comprise a chaperone. As would be known to those of skill in the art, the fusion protein, also referred to herein as “fused proteins”, comprising the antigen may be generated via recombinant methods well-known to those of skill in the art. The antigen and translocation domain, and the optional chaperone, may be joined directly or by a linker; appropriate linkers would be well-known to those of skill in the art.
- By the term “translocation domain”, it is meant a protein domain or fragment thereof that directs translocation of a protein from the phagosome to the cytosol of the host cell. The translocation domain may be any suitable translocation domain from known type III secretion systems of bacteria, which are well-known to those of skill in the art. For example, and without wishing to be limiting in any manner, the translocation domain may be YopE or a fragment thereof. YopE is a 23kDa protein comprising a N-terminal secretion domain of approximately 11 amino acids and a translocation domain of at least 50 aa. In one specific, non-limiting example, the YopE translocation domain may comprise the sequence:
-
(SEQ ID NO: 1) MKISSFISTSLPLPTSVSGSSSVGEMSGRSVSQQKSEQYANNLAGRT ESPQGSSLASRITEKLSSMARSAIEFIKRMFSEGSHKPVVTPAPTPA QMPSPTSFSDSIKQLAAETLPKYIQQLSSLDAETLQKNHDQFAT,
a fragment thereof (such as, but not limited to MKISSFISTSLPLPTSVS, SEQ ID NO:2), or a sequence substantially identical thereto. Another suitable translocation domain may be the SptP protein of ST (Russmann et al., 1998); again, the SptP translocation domain could be the full length protein or a truncated version thereof. In one specific example, the SptP translocation domain may comprise the sequence: -
(SEQ ID NO: 3) MLKYEERKLNNLTLSSFSKVGVSNDARLYIAKENTDKAYVAPEKFSSKVL TWLGKMPLFKNTEVVQKHTENIRVQDQKILQTFLHALTEKYGETAVNDAL LMSRINMNKPLTQRLAVQITECVKAADEGFINLIKSKDNVGVRNAALVIK GGDTKVAEKNNDVGAESKQPLLDIALKGLKRTLPQLEQMDGNSLRENFQE MASGNGPLRSLMTNLQNLNKIPEAKQLNDYVTTLTNIQVGVARFSQWGTC GGEVERWVDKASTHELTQAVKKIHVIAKELKNVTAELEKIEAGAPMPQTM SGPTLGLARFAVSSIPINQQTQVKLSDGMPVPVNTLTFDGKPVALAGSYP KNTPDALEAHMKMLLEKECSCLVVLTSEDQMQAKQLPPYFRGSYTFGEVH TNSQKVSSASQGEAIDQYNMQLSCGEKRYTIPVLHVKNWPDHQPLPSTDQ LEYLADRVKNSNQNGAPGRSSSDKHLPMIHCLGGVGRTGTMAAALVLKDN PHSNLEQVRADFRDSRNNRMLEDASQFVQLKAMQAQLLMTTAS,
a fragment thereof, or a sequence substantially identical thereto. Yet another example of a suitable translocation domain is SopE, a type III secretion protein in Salmonella ST (Zhu et al., 2010). In a specific example, the SopE translocation domain may comprise the -
sequence: (SEQ ID NO: 4) MTKITLSPQNFRIQKQETTLLKEKSTEKNSLAKSILAVKNHFIELRSKLS ERFISHKNTESSATHFHRGSASEGRAVLTNKVVKDFMLQTLNDIDIRGSA SKDPAYASQTREAILSAVYSKNKDQCCNLLISKGINIAPFLQEIGEAAKN AGLPGTTKNDVFTPSGAGANPFITPLISSANSKYPRMFINQHQQASFKIY AEKIIMTEVAPLFNECAMPTPQQFQLILENIANKYIQNTP,
a fragment thereof, or a sequence substantially identical thereto. - The fusion protein may optionally comprise a chaperone. By the term “chaperone’, it is meant a protein that assists in translocation of the immunodominant antigen. The chaperone protein may be any suitable protein known in the art, and must be compatible with translocation domain chosen. The chaperone may also be from a type III secretion system. For example, and without wishing to be limiting, the chaperone may be SycE. SycE is a YopE-specific chaperone that is required for YopE-mediated translocation of fused proteins to the cytosol (Russmann et al., 2001). SycE assists in translocation of the fused protein into the cytosol of infected cells through the type III secretion system of ST. In a specific, non-limiting example, the SycE chaperone may comprise the sequence:
-
(SEQ ID NO: 5) MYSFEQAITQLFQQLSLSIPDTIEPVIGVKVGEFACHITEHPVGQILMF TLPSLDNNNEKETLLSHNIFSQDILKPILSWDEVGGHPVLWNRQPLNNL DNNSLYTQLEMLVQGAERLQTSSLISPPRSFS,
or a sequence substantially identical thereto. In another example, the SopE translocation domain has been used in combination with the chaperone protein heat shock protein 70 (Hsp70) to deliver an antigen to the cytosol (Zhu et al., 2010). In a specific, non-limiting example, the chaperone may comprise the sequence: -
(SEQ ID NO: 6) MGKIIGIDLGTTNSCVAIMDGTQARVLENAEGDRTTPSIIAYTQDGETLV GQPAKRQAVTNPQNTLFAIKRLIGRRFQDEEVQRDVSIMPYKIIGADNGD AWLDVKGQKMAPPQISAEVLKKMKKTAEDYLGEPVTEAVITVPAYFNDAQ RQATKDAGRIAGLEVKRIINEPTAAALAYGLDKEVGNRTIAVYDLGGGTF DISIIEIDEVDGEKTFEVLATNGDTHLGGEDFDTRLINYLVDEFKKDQGI DLRNDPLAMQRLKEAAEKAKIELSSAQQTDVNLPYITADATGPKHMNIKV TRAKLESLVEDLVNRSIEPLKVALQDAGLSVSDINDVILVGGQTRMPMVQ KKVAEFFGKEPRKDVNPDEAVAIGAAVQGGVLTGDVKDVLLLDVTPLSLG IETMGGVMTPLITKNTTIPTKHSQVFSTAEDNQSAVTIHVLQGERKRASD NKSLGQFNLDGINPAPRGMPQIEVTFDIDADGILHVSAKDKNSGKEQKIT IKASSGLNEEEIQKMVRDAEANAESDRKFEELVQTRNQGDHLLHSTRKQV EEAGDKLPADDKTAIESALNALETALKGEDKAAIEAKMQELAQVSQKLME IAQQQHAQQQAGSADASANNAKDDDVVDAEFEEVKDKK,
or a sequence substantially identical thereto. The inclusion of the chaperone is optional, as the translocation domain, or a fragment thereof, alone may be sufficient to cause translocation of the antigen to the cytosol; for example, and without wishing to be limiting, YopE alone, or an 18-amino acid fragment thereof (MKISSFISTSLPLPTSVS, SEQ ID NO:2) are presently shown to produce the desired effect. Similarly, expression of the endogenous Salmonella chaperone protein InvB is sufficient to mediate the translocation function of SopE (Lee and Galan, 2003). - In one specific example of the present invention, the recombinant bacterium comprises a nucleic acid encoding an antigen comprising a fusion protein comprising the sequence of SycE, YopE, and ovalbumin:
-
(SEQ ID NO: 7) MYSFEQAITQLFQQLSLSIPDTIEPVIGVKVGEFACHITEHPVGQILMFT LPSLDNNNEKETLLSHNIFSQDILKPILSWDEVGGHPVLWNRQPLNNLDN NSLYTQLEMLVQGAERLQTSSLISPPRSFSMKISSFISTSLPLPTSVSGS SSVGEMSGRSVSQQKSEQYANNLAGRTESPQGSSLASRITEKLSSMARSA IEFIKRMFSEGSHKPVVTPAPTPAQMPSPTSFSDSIKQLAAETLPKYIQQ LSSLDAETLQKNHDQFATGSNFQTAADQARELINSRVESQTNGIIRNVLQ PSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQESKPVQMMY QIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFE KLTEWTSSNVMEERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANL SGISSAESLKISQAVHAAHAEINEAGREVVGSAEAGVDAASVSEEFRADH PFLFCIKHIATNAVLFFGRCVSP,
a fusion protein comprising the sequence of SycE, a fragment of YopE, and ovalbumin: -
(SEQ ID NO: 8) MYSFEQAITQLFQQLSLSIPDTIEPVIGVKVGEFACHITEHPVGQILMFT LPSLDNNNEKETLLSHNIFSQDILKPILSWDEVGGHPVLWNRQPLNNLDN NSLYTQLEMLVQGAERLQTSSLISPPRSFSMKISSFISTSLPLPTSVSGS NFQTAADQARELINSRVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKG LWEKAFKDEDTQAMPFRVTEQESKPVQMMYQIGLFRVASMASEKMKILEL PFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVMEERKIKVYL PRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHA EINEAGREVVGSAEAGVDAASVSEEFRADHPFLFCIKHIATNAVLFFGRC VSP,
a fusion protein comprising the sequence of a fragment of YopE and ovalbumin: -
(SEQ ID NO: 9) MKISSFISTSLPLPTSVSGSNFQTAADQARELINSRVESQTNGIIRNVLQ PSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQESKPVQMMY QIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFE KLTEWTSSNVMEERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANL SGISSAESLKISQAVHAAHAEINEAGREVVGSAEAGVDAASVSEEFRADH PFLFCIKHIATNAVLFFGRCVSP,
a fusion protein comprising the sequence of SycE, YopE, and TRP-2: -
(SEQ ID NO: 10) MYSFEQAITQLFQQLSLSIPDTIEPVIGVKVGEFACHITEHPVGQILMFT LPSLDNNNEKETLLSHNIFSQDILKPILSWDEVGGHPVLWNRQPLNNLDN NSLYTQLEMLVQGAERLQTSSLISPPRSFSMKISSFISTSLPLPTSVSGS SSVGEMSGRSVSQQKSEQYANNLAGRTESPQGSSLASRITEKLSSMARSA IEFIKRMFSEGSHKPVVTPAPTPAQMPSPTSFSDSIKQLAAETLPKYIQQ LSSLDAETLQKNHDQFATMKISSFISTSLPLPTSVSGSSSVGEMSGRSVS QQKSEQYANNLAGRTESPQGSSLASRITEKLSSMARSAIEFIKRMFSEGS HKPVVTPAPTPAQMPSPTSFSDSIKQLAAETLPKYIQQLSSLDAETLQKN HDQFATGSGILLRARAQFPRVCMTLDGVLNKECCPPLGPEATNICGFLEG RGQCAEVQTDTRPWSGPYILRNQDDREQWPRKFFNRTCKCTGNFAGYNCG GCKFGWTGPDCNRKKPAILRRNIHSLTAQEREQFLGALDLAKKSIHPDYV ITTQHWLGLLGPNGTQPQIANFSVYDFFVWLHYYSVRDTLLGPGRPYKAI DFSHQGPAFVTWH,
a fusion protein comprising the sequence of SycE, YopE, and gp100: -
(SEQ ID NO: 11) MYSFEQAITQLFQQLSLSIPDTIEPVIGVKVGEFACHITEHPVGQILMFT LPSLDNNNEKETLLSNIFSQDILKPILSWDEVGGHPVLWNRQPLNSLDNN SLYTQLEMLVQGAERLQTSSLISPPRSFSMKISSFISTSLPLPASVSGSS SVGEMSGRSVSQQKSDQYANNLAGRTESPQGSSLASRIIERLSSMAHSVI GFIQRMFSEGSHKPVVTPALTPAQMPSPTSFSDSIKQLAAETLPKYMQQL SSLDAETLQKNHDQFATGSGKNTMDLVLKRCLLHLAVIGALLAVGATKVP RNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRGGQVSLKVSNDGPTL IGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVYPQETD DACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRA MLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDG GNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVT HTYLEPGPVTAQVVLQAAIPLT,
a fusion protein comprising the nuclear protein of SycE, YopE, and LCMV-NP: -
(SEQ ID NO: 12) MYSFEQAITQLFQQLSLSIPDTIEPVIGVKVGEFACHITEHPVGQILMFT LPSLDNNNEKETLLSHNIFSQDILKPILSWDEVGGHPVLWNRQPLNNLDN NSLYTQLEMLVQGAERLQTSSLISPPRSFSMKISSFISTSLPLPTSVSGS SSVGEMSGRSVSQQKSEQYANNLAGRTESPQGSSLASRITEKLSSMAHSA IEFIKRMFSEGSHKPVVTPAPTPAQMPSPTSFSDSIKQLAAETLPKYMQQ LSSLDAETLQKNHDQFATGSFVSDQVGDRNPYENILYKVCLSGEGWPYIA CRTSIVGRAWENTTIDLTSEKPAVNSPRPAPGAAGPPQVGLSYSQTMLLK DLMGGIDPNAPTWIDIEGRFNDPVEIAIFQPQNGQFIHFYREPVDQKQFK QDSKYSHGMDLADLFNAQPGLTSSVIGALPQGMVLSCQGSDDIRKLLDSQ NRKDIKLIDVEMTREASREYEDKVWDKYGWLCKMHTGIVRD, - or a sequence substantially identical thereto. The fusion protein further comprises the sequence of the antigen of interest.
- A substantially identical sequence may comprise one or more conservative amino acid mutations. It is known in the art that one or more conservative amino acid mutations to a reference sequence may yield a mutant peptide with no substantial change in physiological, chemical, or functional properties compared to the reference sequence; in such a case, the reference and mutant sequences would be considered “substantially identical” polypeptides. Conservative amino acid mutation may include addition, deletion, or substitution of an amino acid; a conservative amino acid substitution is defined herein as the substitution of an amino acid residue for another amino acid residue with similar chemical properties (e.g. size, charge, or polarity).
- In a non-limiting example, a conservative mutation may be an amino acid substitution. Such a conservative amino acid substitution may substitute a basic, neutral, hydrophobic, or acidic amino acid for another of the same group. By the term “basic amino acid” it is meant hydrophilic amino acids having a side chain pK value of greater than 7, which are typically positively charged at physiological pH. Basic amino acids include histidine (His or H), arginine (Arg or R), and lysine (Lys or K). By the term “neutral amino acid” (also “polar amino acid”), it is meant hydrophilic amino acids having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Polar amino acids include serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N), and glutamine (Gln or Q). The term “hydrophobic amino acid” (also “non-polar amino acid”) is meant to include amino acids exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg (1984). Hydrophobic amino acids include proline (Pro or P), isoleucine (Ile or I), phenylalanine (Phe or F), valine (Val or V), leucine (Leu or L), tryptophan (Trp or W), methionine (Met or M), alanine (Ala or A), and glycine (Gly or G). “Acidic amino acid” refers to hydrophilic amino acids having a side chain pK value of less than 7, which are typically negatively charged at physiological pH. Acidic amino acids include glutamate (Glu or E), and aspartate (Asp or D).
- Sequence identity is used to evaluate the similarity of two sequences; it is determined by calculating the percent of residues that are the same when the two sequences are aligned for maximum correspondence between residue positions. Any known method may be used to calculate sequence identity; for example, computer software is available to calculate sequence identity. Without wishing to be limiting, sequence identity can be calculated by software such as NCBI BLAST2 service maintained by the Swiss Institute of Bioinformatics (and as found at http://ca.expasy.org/tools/blast/), BLAST-P, Blast-N, or FASTA-N, or any other appropriate software that is known in the art.
- The substantially identical sequences of the present invention may be at least 70%, 80%, 90%, or 95% identical; in another example, the substantially identical sequences may be at least 70, 71, 72, 73, 74, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical at the amino acid level to sequences described herein. Importantly, the substantially identical sequences retain the activity and specificity of the reference sequence.
- The present invention also encompasses nucleic acids encoding the antigen as described above, as well as vectors comprising the nucleic acid.
- Thus, the recombinant bacterium of the present invention may comprise a nucleic acid encoding the antigen as described above, or may comprise a vector (also referred to herein as“plasmid”) comprising such nucleic acid that is fused with the nucleic acid of a translocation domain and optionally the nucleic acid of a chaperone; for example, and without wishing to be limiting in any manner, the vector in which antigen is translocated to the cytosol of infected cells may be a modified pHR plasmid. The modified pHR construct uses the type III secretion protein to generate fusion proteins that are transported out of the phagosome and through the host bacterial type III secretion system for direct cytosolic antigen presentation. The pHR constructs may comprise sequences encoding a translocation domain and optionally a chaperone protein to aid in proper trafficking of the downstream fusion protein. In a specific, non-limiting example, the vector may be a modified pHR-241 plasmid (Russmann et al., 2001); more specifically, the pHR-241 comprising the sequence of SycE-YopE-p60/M45 fusion protein (Russmann et al., 2000) modified to remove the sequence of p60/M45. In another example, the pHR241 vector is modified to comprise YopE or a fragment of YopE (for example, but not limited to MKISSFISTSLPLPTSVS, SEQ ID NO:2) with the sequence for the SycE and p60/M45 proteins removed. Replacement of the antigenic sequence by appropriate restriction enzymes and subsequent ligation of other antigens would result in development of the desired CD8+ T cell response against said antigens upon vaccination. Furthermore, the recombinant bacterium that harbors this plasmid need not be a highly virulent bacterium; for example, attenuated Salmonella is presently shown to be effective at inducing the desired response. The response can be accentuated further by vaccination with higher doses of the attenuated strain.
- The recombinant bacterium as described above may be utilized to impart immunity against other naturally-occurring and virulent bacteria. This may be accomplished by administering an effective amount of the recombinant bacterium of the present invention to a subject, and allowing a CD8+ T cell response to be mounted. Similarly, the recombinant bacterium may be utilized to impart immunity against tumors in a subject, by administering an effective amount of the recombinant bacterium of the present invention to said subject. In both methods, the recombinant bacterium may be administered through intravenous, oral or subcutaneous routes of immunization. This approach avoids the unwanted side-effects of persisting bacteria and undesirable toxicity/inflammation associated with live vaccines. Thus, higher doses of the vaccine can be used for improved efficacy. Because the recombinant bacterium of the present invention is eliminated after a few weeks, there is little concern regarding toxicity. Furthermore, Salmonella when given orally induces a mucosal CD8+ T cell response (Jones and Falkow, 1996). Thus, the modified bacterium can be administered through the oral route for induction of the desired CD8+ T cell response.
- The recombinant bacterium as described above may also be utilized as a vaccine; the vaccine may protect against other naturally-occurring and virulent bacteria, other bacterial pathogens, viral pathogens, or tumors. When the antigen is a tumour-antigen, the tumour-antigen will be translocated to the host cell cytosol, resulting in rapid activation of tumor-specific CD8+ T cells, which will translate to better tumour control by tumor-specific CD8+ T cells.
- A recombinant ST that injects an antigen directly into the host cytosol has presently been developed. This results in profound CD8+ T cell activation and consequent elimination of ST. It is also shown that when CD8+ T cells are engaged in this manner, they undergo profound expansion which results in massive pathogen and tumour control as well as abridgment of pathogen chronicity. The present data provide novel insights into the incapacity of the immune system to efficiently control the bacterium, as well as reveal the power of the acquired immune system, wherein engagement of potent antigen-presentation early on may be sufficient to control an otherwise uncontrollable bacterium. The present results provide compelling evidence that modulation of the cell biology of antigen trafficking is a key avenue that is employed by various pathogens for immune evasion. The recombinant bacterium described herein may be used as a novel vaccine, wherein a key modification makes the bacterium generate rapid, potent CD8+ T cell response, resulting in self-destruction of the vaccine in vivo, making it highly efficacious, safe and cost-effective.
- The utility of the recombinant bacterium described herein is demonstrated using OVA, TRP-2, and gp-100 as antigens. Using a similar approach, other putative antigens from other pathogens (bacteria, virus) or tumours can be cloned into the recombinant bacterium; these antigens can then be translocated into the host cell cytosol for rapid and potent antigen-presentation using the a translocation domain/chaperone system.
- The present invention will be further illustrated in the following examples. However, it is to be understood that these examples are for illustrative purposes only and should not be used to limit the scope of the present invention in any manner.
- Recombinant bacteria comprising Salmonella enterica, serovar Typhimurium (ST) expressing ovalbumin (OVA) were prepared. Construct ST-OVA-NT, which does not translocate antigen to the cytosol, was prepared as previously described (Luu et al., 2006). A recombinant construct, ST-OVA-T, that produces an OVA fusion protein that is translocated to the cytosol;
FIG. 1A shows a schematic of the fusion protein, where OVA is fused to YopE and SycE. YopE is a 23 kDa protein comprising a N-terminal secretion domain (˜11 aa) and a translocation domain (at least 50 aa); the latter domain provides the binding site for the YopE-specific chaperone (SycE) that is required for YopE-mediated translocation of fused proteins to the cytosol (R). SycE is a chaperone necessary for translocation of the fused protein into the cytosol of infected cells through the type III secretion system of ST. A schematic of both ST-OVA-NT and ST-OVA-T constructs and their proposed actions are shown inFIG. 1B . - Plasmid pHR-OVA was constructed by the modification of the plasmid pHR-241 (Russmann et al., 2001), which contains the sequence of the fusion protein SycE-YopE-p60/M45 (Russmann et al., 2000). In a first step, the genes of p60/M45 were removed by cutting plasmid pHR-241 with BamHl and Kpnl. Then, the pKK-OVA plasmid was purified from the recombinant ST-OVA-NT bacteria by mid prep kit (Invitrogen, US) according to the manufacturer's instructions. The OVA gene was PCR-amplified using the plasmid pKK-OVA as a template (
forward primer BamHl 5′-CGGGATCCAACTTTCAAACAGCTG-3′ (SEQ ID NO:13) andreverse primer Kpnl 5′-GGGGTACCTTAAGGGGAAACACATC-3′ (SEQ ID NO:14). Subsequently, the OVA gene was inserted between the BamHl-Kpnl sites of the cut pHR-241 palsmid, creating new plasmid pHR-OVA. PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C. The amplified insert was ligated into the intended vector then sequenced to verify the accuracy of the amplified cDNA. The pHR-OVA plasmid was then transfected into the highly virulent ST (strain SL1344). 50 μL of electrocompetent Salmonella (WT or aroA) were mixed with ˜20 ng plasmid DNA and pulsed in a Bio-Rad micropulser using one pulse of 2.5 kV. Immediately afterwards, 1 mL of SOC recovery medium was added to the bacteria and they were allowed to recover with shaking at 37° C. The bacteria were then plated on LB agar plates with ampicillin for the selection of individual clones. - ST-OVA-NT and ST-OVA-T constructs of Example 1 were grown and expression and translocation of ovalbumin was evaluated. Pellet and supernatant of ST-OVA-NT and ST-OVA-T growing in liquid cultures were tested for the presence of OVA.
- C57BL/6J mice were injected intravenously with 106 ST-OVA-NT or ST-OVA-T reconstituted in 200 microlitres normal saline. Two days later, spleens were obtained from infected mice; spleen cells were isolated and lysed with TRITON X-100 in the presence of protease inhibitor, phenylmethylsulfonyl fluoride. The soluble lysate containing cytosolic proteins was tested for OVA expression by western blotting. Samples were normalized for cell number and were loaded on SDS-10% polyacrylamide gels. SDS-PAGE was performed and proteins were transferred to membranes, which were then blocked with 5% skim milk powder in PBS-TWEEN. OVA expression was detected using a 1/10,000 dilution of polyclonal anti-OVA antibody (Sigma-Aldrich), followed by incubation with HRP-conjugated goat anti-rabbit Ab ( 1/5,000 dilution in PBS-TWEEN) from Roche Applied Science. Immuno-reactive bands were detected with enhanced chemiluminescence substrate (Roche Applied Bioscience). Results show that OVA-expression by ST-OVA-NT and ST-OVA-T (from ˜5×106) in the bacterial pellets was similar (
FIG. 1C ). However, OVA could only be detected in the supernatant of ST-OVA-T cultures. Expression of OVA was detectable in the cytosol of spleen cells from mice infected with ST-OVA-T- but not ST-OVA-NT (FIG. 1C ). - The ability of ST-OVA to proliferate extra- and intra-cellularly was also analyzed.
- Liquid cultures of ST-OVA-NT and ST-OVA-T were set up in flasks to enumerate extracellular proliferation. At various time intervals (eg, 60 min., 120 min., 240 min., etc), aliquots were removed for measurement of OD at 600 nm. Both ST-OVA-NT and ST-OVA-T displayed similar proliferation and doubling time (
FIG. 2A ). - The influence of antigenic translocation on the ability of ST-OVA to proliferate within the intracellular compartment was evaluated. IC-21 macrophages (H-2b) (5×104/well) were infected with ST-OVA-NT or ST-OVA-T (MOI=10). After 30 min, cells were washed and cultured in media containing gentamicin (50 μg/ml) to remove extracellular bacteria. After 2 h, cells were washed again and cultured in media containing reduced levels of gentamicin (10 μg/ml). At various time intervals cells were lysed and bacterial burden in the cells determined. No statistically significant difference was detected in the ability of ST-OVA-NT or ST-OVA-T to infect and replicate within macrophages (p>0.05). Results are shown in
FIG. 2B and are representative of three independent experiments. Thus, the ability of ST-OVA to infect and survive within macrophages in vitro was not influenced by antigenic translocation. - It was previously reported that ST-OVA-NT infection does not induce a detectable CD8+ T cell response within the first week of infection (Luu et al., 2006), due to delayed presentation of antigen to CD8+ T cells (Albaghdadi et al., 2009). Therefore, it was evaluated whether translocation of antigen to the cytosol would result in rapid antigen-presentation.
- In vitro antigen-presentation was performed as previously described (Albaghdadi et al., 2009). IC-21 macrophages (H-2b) cells (105/well) were infected with different MOI of ST (Albaghdadi et al., 2009), ST-OVA-NT (Example 1), or ST-OVA-T (Example 1) for 30 min. Extracellular bacteria were removed after incubation in medium containing gentamicin (50 μg/ml). At 2 h, cells were cultured in media containing lower levels of gentamicin (10 μg/ml) and incubated with CFSE-labelled OT-1 (CD45.1+45.2−) TCR transgenic cells (106/well). After 4 days of culture, cells were harvested, stained with anti-CD45.1 and anti-CD8 antibodies, and the reduction in CFSE intensity of OT-1 CD8+ T cells was evaluated by flow cytometry.
- Infection of macrophages with ST or ST-OVA-NT did not result in any detectable proliferation of OT-1 cells, indicating lack of antigen-presentation (
FIG. 3A ). Interestingly, infection with ST-OVA-T, even at reduced doses, resulted in strong dilution of CFSE expression, which is indicative of rapid and potent antigen-presentation in vitro (FIG. 3A ). - In vivo antigen-presentation was done as previously described (Albaghdadi et al., 2009). B6129F1 mice were infected with the recombinant bacteria of Example 1, followed by adoptive transfer of CFSE labelled OT-1 cells. B6.129F1 mice were used because B6 parents are highly susceptible and die within the first week of infection (Albaghdadi et al., 2009). Briefly, B6129F1 mice were generated in house by mating 129×1 SvJ female mice with C57BL/6J male mice; mice were obtained from The Jackson Laboratory and were maintained at the Institute for Biological Sciences (National Research Council of Canada, Ottawa, Canada) in accordance with the guidelines of the Canadian Council on Animal Care. For immunization, frozen stocks of ST-OVA-NT or ST-OVA-T (Example 1) were thawed and diluted in 0.9% NaCl; mice were inoculated (iv) with 103 organisms suspended in 200 μl. At various time intervals, CFSE-labelled OT-1 cells were injected (5×106, iv). Four days after the transfer of OT-1 cells, spleens were isolated from recipient mice and spleen cells were stained with OVA-tetramer and anti-CD8 antibody. Reduction in the expression of CFSE intensity was evaluated by flow cytometry, as described above.
- Results are shown in
FIGS. 3B and 3C ; results represent the mean of three mice ±SD per group, and are representative of two-three independent experiments. Atday 5 of infection, the majority of transferred OT-1 cells displayed reduced expression of CFSE in mice infected with ST-OVA-T (FIG. 3B ). In contrast, OT-1 cells in ST-OVA-NT-infected mice maintained high levels of CFSE expression. When in vivo antigen-presentation was evaluated kinetically, ST-OVA-NT infected mice displayed muted and delayed activation of CFSE-labelled OT-1 cells (FIG. 3C ). Interestingly, the massive antigen-presentation that was induced early on in ST-OVA-T infected mice was subsequently reduced to baseline levels as the pathogen was cleared. - Example 5: Antigen translocation and CD8+ T cell response
- The question of whether the induction of rapid antigen-presentation in vitro and in vivo by antigenic translocation to the cytosol would result in the development of a rapid CD8+ T cell response in vivo and whether this had any influence on pathogen control was examined.
- B6.129F1 mice were infected (103, iv) with ST-OVA-T or ST-OVA-NT without any adoptive transfer of OT-1 cells. At various time intervals, the numbers of spleen cells, spleen size and bacterial burden were evaluated. OVA-specific CD8+ T cell response was enumerated by Flow cytometry. Briefly, aliquots of spleen cells (5×106) were incubated in 80 μl of PBS plus 1% BSA (PBS-BSA) with anti-CD16/32 at 4° C. After 10 min., cells were stained with H-2KbOVA257-264 tetramer-PE (Beckman Coulter, US) and various antibodies (anti-CD8 PerCP-Cy5, anti-CD62L APC-Cy7, and anti-CD127 (PE-Cy7) for 30 min. All antibodies were obtained from BD Biosciences. Cells were washed with PBS, fixed in 0.5% formaldehyde and acquired on a BD Biosciences FACSCanto analyzer.
- Results are shown in
FIG. 4 ; these results represent the mean of three to five mice ±SD per group and are representative of three independent experiments. Infection of mice with ST-OVA-T resulted in the development of a rapid and potent OVA-specific CD8+ T cell response as evaluated by staining with OVA-tetramers (FIG. 4D, 4E ;FIG. 5A ); these mice displayed reduced spleen cell numbers and size (FIG. 4A, 4B ). Atday 3 of infection, similar bacterial burdens were noted in mice that received ST-OVA-T or ST-OVA-NT (FIG. 4C ). However, at subsequent time intervals, the burden of ST-OVA-T were enormously controlled which was reduced to non-detectable levels byday 30. In contrast, ST-OVA-NT burden was maintained at high levels and the burden was detectable even at day 60 (FIG. 4C ). Interestingly, atday 60, while both groups of mice had similar numbers of OVA-tetramer+ cells (FIG. 4E ), the ST-OVA-T group of mice had controlled the burden whereas the ST-OVA-NT group of mice failed to control it (FIG. 4C ); this suggests that direct antigen-presentation in case of ST-OVA-T makes the targets susceptible. - Phenotypic analysis of OVA-specific CD8+T cells induced against ST-OVA-T versus ST-OVA-NT was also performed.
FIG. 5A shows the OVA-tetramer profile in the spleens of infected mice, and the expression (MFI) of CD62L (FIG. 5B, 5D ) and CD127 (FIG. 5C, 5D ) on OVA-tetramer+CD8+T cells. In contrast to ST-OVA-NT, OVA-specific CD8+T cells induced against ST-OVA-T displayed rapid activation (CD62L down-regulation) and rapid progression to the memory state (CD127 up-regulation) (FIG. 5B-D ). Taken together, these results clearly indicate that antigenic translocation to the cytosol in the context of ST infection accelerates the kinetics and increases the potency of antigen-presentation, CD8+T cell differentiation, and memory development. Thus, the differentiation of CD8+T cells that is noted with ST-OVA-T infection mirrors the one that is induced against the potent pathogen, LM. - Given the results noted with antigenic translocation in resistant mice (Example 5), determination of whether the rapid induction of CD8+T cells would influence the survival of susceptible C57BL/6J mice was undertaken.
- C57BL/6J mice were infected (103, iv) with ST-OVA-T or ST-OVA-NT. At different time points (
day - Results are shown in
FIG. 6 and represent the mean of three to four mice ±SD per group; results are representative of two independent experiments. Atdays FIG. 6A ). At later time periods, while the bacterial burden in ST-OVA-NT-infected mice continued to increase exponentially to lethal levels, the burden in ST-OVA-T-infected mice was rapidly controlled and became undetectable afterday 14. Abridgment of bacterial burden in ST-OVA-T-infected mice correlated to the early emergence of potent OVA-specific CD8+T cell response, as detected by OVA-tetramer staining (FIG. 6B-C ) that peaked atday 7. - Two functional assays were carried out to determine whether the CD8+ T cells that were induced by antigenic translocation would result in induction of CD8+ T cells that mediate appropriate functions.
- Enumeration of IFN-y secreting cells was performed by ELISPOT assay as reported previously at
day 7 of infection (Dudani et al., 2002). ST-OVA-T-infected mice mounted a profound CD8+ T cell response (FIG. 6D ), indicative of IFN-y production. In contrast, infection of susceptible mice with ST-OVA-NT did not result in any detectable IFN-γ-secreting CD8+ T cells. - The ability of stimulated CD8+ T cells to kill target cells specifically was enumerated as another functional readout. To do this, CFSE-labelled, OVA-pulsed and control spleen cells from naïve mice were transferred to ST-OVA-T- and ST-OVA-NT-infected mice on
day 7, and the specific killing of OVA-pulsed targets was evaluated. In vivo cytolytic activity of CD8+ T cells was performed according to previously published reports (Luu et al., 2006; Barber et al., 2003). OVA-specific CD8+ T cells that were induced atday 7 in ST-OVA-T-infected mice displayed rapid, potent and specific cytolytic activity towards OVA-pulsed target cells (FIG. 6E-F ). In contrast, ST-OVA-NT-infected mice displayed little cytolytic activity, as expected (Luu et al., 2006). Thus, the kinetics of CD8+ T cells response in ST-OVA-T infected susceptible C57BL/6J was similar to that observed in resistant B6.129 F1 mice, as was their phenotype. -
FIG. 7 shows results of phenotypic analysis of OVA-specific CD8+ T cells induced against ST-OVA-T versus ST-OVA-NT. Similar to the profile in resistant mice, OVA-specific CD8+ T cells induced against ST-OVA-T in susceptible mice displayed rapid down-regulation of CD62L and rapid transition to the memory phenotype (increased CD127 up-regulation;FIG. 7 ). - While the data of Example 6 indicated that rapid emergence of functional CD8+ T cells by antigenic translocation can control ST burden rapidly, it was still correlative. In order to test if the rapid emergence of CD8+ T cells are responsible for elimination of bacteria during ST-OVA-T infection, C57BL/6J mice were treated with anti-CD8 or anti-CD4 antibody or isotype control then infected with ST-OVA-T to eliminate those cells specifically. C57BL/6J mice were treated with (100 μg/injection) anti-CD4 (clone GK1.5), anti-CD8 (clone 2.43), or Rat IgG isotype antibodies on days −3, 0 and 3 after infection with 103 ST-OVA-T. At
day 7 after infection, spleens were harvested and the bacterial burden evaluated. Atday 7 after infection, anti-CD8 antibody treated mice had a >100-fold higher ST-OVA-T burden (FIG. 8A ), suggesting that when CD8+ T cells are depleted, ST-OVA-T cannot be controlled by the host. Depletion of CD4+ T cells had no effect on the bacterial burden. - The importance of CD8+ T cells in controlling bacterial burden was further confirmed by infecting WT, MHC-I or MHC-II-deficient C57BL/6J mice with ST-OVA-T. Since MHC class I deficient mice lack CD8+ T cells they should be susceptible to infection. Twenty days after infection, MHC-I deficient mice were moribund, displaying very high bacterial loads (
FIG. 8B ) whereas control mice had undetectable burden, and MHC class II-deficient hosts (lacking CD4+ T cells) showed only a minor effect. MHC-I deficient mice were sick due to high bacterial loads, while MHC-II-deficient and WT mice were healthy. Taken together, these results indicate that antigenic translocation to cytosol in the context of ST infection results in a rapid emergence of a potent CD8+ T cell response which is sufficient to control the burden. - In order to design vaccines, attenuated strains of bacteria are often used to avoid undesirable toxicity that occurs with highly virulent bacteria. It was therefore determined whether translocation of OVA in a highly attenuated strain of ST (ΔaroA) would induce rapid activation of CD8+ T cells.
- B6.129F1 mice were infected with 103 (virulent) wild type (WT; SL1344)) or 105 attenuated (avirulent; ΔaroA) ST-OVA expressing non-translocated or non-translocated OVA. At various time intervals (
day - Results in
FIG. 9 represent the mean of five mice ±SD per group. Translocation of OVA by avirulent ST also resulted in rapid and profound induction of OVA-specific CD8+ T cell response in the spleen (FIG. 9A ) and peripheral blood (FIG. 9B ). Thus, these results indicate that antigenic translocation works equally well for virulent and avirulent bacteria. - It was also investigated whether antigenic translocation would result in effective protection upon tumour challenge.
- C57BL/6J mice were infected with 103 ST-OVA-T; non-infected (naïve) mice served as controls. On
day 60, mice were challenged subcutaneously in the lower dorsal region with 106 B16 melanoma cells carrying the OVA gene (B16-OVA). Survival of mice was measured subsequently. As shown inFIG. 10A , prophylactic vaccination with ST-OVA-T resulted in potent protection against tumour challenge. Protection in a therapeutic model, where mice were first challenged with tumours and then vaccinated with immunogens, was also tested. B6.129F1 mice were challenged first with 106 B16-OVA tumour cells subcutaneously in the lower dorsal region. Three days later, mice were vaccinated with ST-OVA-NT or ST-OVA-T. Non-infected mice served as negative controls and LM-OVA infected mice served as positive controls. At various time intervals subsequently, survival of mice was monitored. Mice receiving ST-OVA-T displayed the best protection against B16 melanoma cells (FIG. 10B ). Protection induced by ST-OVA-T was far greater than that induced by ST-OVA-NT and LM-OVA. Results represent the mean of five mice ±SD per group. - The use of OVA as an immunodominant antigen is described herein as a proof of principle. Using a similar approach, other putative antigens from other pathogens (bacteria, virus) or tumours can be cloned into ST and these antigens can be translocated into the host cell cytosol for rapid and potent antigen-presentation using the YopE/SycE system.
- The gene for the tumour-antigen (Trp-2) (Schumacher and Restifo, 2009) was cloned into the WT or aroA mutant of ST, which translocates antigen to the cytosol. PCR was done using pCDNA3-Trp2 as template using the following primers:
-
Forward primer: (SEQ ID NO: 15) TAGGATCCGGAATTCTGCTCAGAG, and Reverse primer: (SEQ ID NO: 16) AGATGGTACCTTTAGTGCCACGTG. - The PCR product and pHR-OVA were digested with BamHl and Kpnl and ligated. PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C. The amplified insert was ligated into the intended vector, then sequenced to verify the accuracy of the amplified cDNA. The PCR product was digested with BgIII and Kpnl; pHR-241 was digested with BamHl and Kpnl and the digested products were ligated. pHR-Trp2 plasmid was then transfected into the highly virulent ST (SL1344) or aroA mutant of ST. 50 μL of electrocompetent Salmonella (WT or aroA) were mixed with ˜20 ng plasmid DNA and pulsed in a Bio-Rad micropulser using one pulse of 2.5 kV. Immediately afterwards, 1 mL of SOC recovery medium was added to the bacteria and they were allowed to recover shaking at 37° C. The bacteria were then plated on LB agar plates with ampicillin for the selection of individual clones.
- [000106] The gene for gp100 tumour-antigen (Rosenberg et al., 2008) was cloned into a pHR or pKK plasmid. PCR was done using pCDNA3-gp100 as template with the following primers:
-
Forward primer: (SEQ ID NO: 17) GAAGATCTGGGAAGAACACAATGG, and Reverse primer: (SEQ ID NO: 18) GGGGTACCTTAGGTGAGAGGAATGG. - The PCR product was digested with BgIII and Kpnl; pHR-241 was digested with BamHl and Kpnl and the digested products were ligated. Infection of B6.129F1 mice with these recombinant nucleic acids resulted in the induction of CD8+ T cell response against Trp-2 (
FIG. 11A ). This was associated with accelerated control of the bacterium (FIG. 11B ,C). Similarly, infection of mice with the gp100 expressing aroA-ST resulted in accelerated control of the bacterium (FIG. 12A ) and induction of a better CD8+ T cell response against gp100 (FIG. 12B ). - The immunodominant epitope recognized to stimulate a CD8+ T cell response from LCMV nucleoprotein (NP) in C57B1/6 mice was also used as an antigen and cloned into ST, and its effect on T cell response in mice was evaluated.
- LCMV-NP was encoded over amino acids 396-404 (FQPQNGQFI) of the protein (Basler et al., 2004). cDNA encoding amino acids 288-463 of the NP protein was cloned into plasmid pKK to generate pKK-NP (
FIG. 13 ), using PCT methods as described in Example 1 and 11. Again, DH5a clones were selected using ampicillin. In this case, Ncol and HindIII restriction sites were added to the oligonucleotides used for amplification of the insert sequence. The oligonucleotide sequences used for the cDNA amplification were: -
(SEQ ID NO: 19) 5' TACCATGGCATTTGTTTCAGACCAAGT 3' and (SEQ ID NO: 20) 5' TAAAGCTTCTAGTCCCTTACTATTCCAG 3'. - The final insert in the pKK plasmid was truncated prior to the end of the amplified insert due to the presence of an internal HindIII restriction site, ending at codon 461. After confirmation of the sequence, this plasmid was also transferred into ST wild type and STΔAro using a standard electroporation protocol (as described below and in Examples 1 and 11). cDNA encoding amino acids 288-461 of the NP protein was similarly cloned into the plasmid, pKK, to generate pKK-NP (
FIG. 13 ). Again, DH5a clones were selected using ampicillin. In this case, Ncol and HindIII restriction sites were added to the oligonucleotides used for amplification of the insert sequence. The oligonucleotide sequences used for the cDNA amplification are: -
(SEQ ID NO: 21) 5' TACCATGGCATttgtttcagaccaaGT 3' and (SEQ ID NO: 22) 5' TAAAGCTTCTAGTCCCTTACTATTCCAG 3'. - The final insert in the pKK plasmid was truncated prior to the end of the amplified insert due to the presence of an internal HindIII restriction site, ending at codon 461. After confirmation of the sequence, this plasmid was also transferred into ST wild type and STΔAro using a standard electroporation protocol. Briefly, 50 μL of electrocompetent Salmonella (WT or aroA) were mixed with ˜20 ng plasmid DNA and pulsed in a Bio-Rad micropulser using one pulse of 2.5 kV. Immediately afterwards, 1 mL of SOC recovery medium was added to the bacteria and they were allowed to recover shaking at 37° C. The bacteria were then plated on LB agar plates with ampicillin for the selection of individual clones. PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C. The amplified insert was ligated into the intended vector then sequenced to verify the accuracy of the amplified cDNA.
- B6.129F1 mice were infected intravenously with 103 recombinant ST expressing NP. Both virulent (
FIG. 13B ,C) and avirulent (FIG. 13D ) ST induced profound NP-specific CD8+ T cell response when NP was translocated to the cytosol. Furthermore, antigenic translocation resulted in decreased bacterial burden (FIG. 13E ) and control of vaccine induced inflammation (FIG. 13F ). - To determine whether the full length YopE was needed for induction of a better CD8+ T cell response, or whether a truncated version of this protein would be sufficient, the gene for OVA was fused with truncated YopE (first eighteen amino acids only), which does not carry the C-terminal domain for binding to the SycE chaperon (
FIG. 14A ). PCR was done using pHR-OVA as template with the following primers: -
Forward primer: (SEQ ID NO: 23) GTGTCAAAGTTGGGGAATTCGC, and Reverse primer: (SEQ ID NO: 24) CTGCTGGATCCTGACACTGATG. - The PCR product and pHR-OVA were digested with EcoRl and BamHl and ligated. PCR amplification of the inserts was performed with Taq polymerase using the following cycling parameters: 94° C., 5 min; 25 cycles of 94° C., 30 s to 58° C., 1 min to 72° C., 1 min; followed by a 7 min extension time at 72° C. The amplified insert was ligated into the intended vector, then sequenced to verify the accuracy of the amplified cDNA.
- B6.129F1 mice were infected with ST-OVA-NT, ST-OVA-T (carrying full length YopE), and ST-OVA-tYopE (carrying truncated YopE). As is clear from results shown in
FIG. 14B , the fusion of the desired antigen with the first eighteen amino acids of YopE is sufficient to induce rapid CD8+ T cell response. CD8+ T cells induced by the truncated YopE differentiated rapidly into memory cells (FIG. 14C ), which lead to curtailment of inflammation (FIG. 14D ) and bacterial burden (FIG. 14E ). - The embodiments and examples described herein are illustrative and are not meant to limit the scope of the invention as claimed. Variations of the foregoing embodiments, including alternatives, modifications and equivalents, are intended by the inventors to be encompassed by the claims. Furthermore, the discussed combination of features might not be necessary for the inventive solution.
- All patents, patent applications and publications referred to herein and throughout the application are hereby incorporated by reference.
- Albaghdadi, H., Robinson, N., Finlay, B., Krishnan, L., and Sad, S. (2009). Selectively reduced intracellular proliferation of Salmonella enterica serovar typhimurium within APCs limits antigen presentation and development of a rapid CD8 T cell response. J Immunol 183, 3778-3787.
Albert, M. L., Pearce, S. F., Francisco, L. M., Sauter, B., Roy, P., Silverstein, R. L., and Bhardwaj, N. (1998). Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359-1368.
Bahjat, K. S., Liu, W., Lemmens, E. E., Schoenberger, S. P., Portnoy, D. A., Dubensky, T. W., Jr., and Brockstedt, D. G. (2006). Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun 74, 6387-6397.
Barber, D. L., Wherry, E. J., and Ahmed, R. (2003). Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171, 27-31.
Basler, M., Youhnovski, N., van den, B. M., Przybylski, M., and Groettrup, M. (2004). Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 173, 3925-3934.
Bevan, M. J. (1995). Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med. 182, 639-641.
Bliska, J. B., Galan, J. E., and Falkow, S. (1993). Signal transduction in the mammalian cell during bacterial attachment and entry. Cell 73, 903-920.
Dudani, R., Chapdelaine, Y., Faassen, H. H., Smith, D. K., Shen, H., Krishnan, L., and Sad, S. (2002). Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J. Immunol. 168, 5737-5745.
Dudani, R., Murali-Krishna, K., Krishnan, L., and Sad, S. (2008). IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intracellular bacterium. J. Immunol. 181, 1700-1709.
Freigang, S., Egger, D., Bienz, K., Hengartner, H., and Zinkernagel, R. M. (2003). Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming. Proc. Natl. Acad.Sci. U. S. A 100, 13477-13482.
Galan, J. E. and Curtiss, R., III (1989). Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells. Proc. Natl. Acad. Sci. U. S. A 86, 6383-6387.
Garvis, S. G., Beuzon, C. R., and Holden, D. W. (2001). A role for the PhoP/Q regulon in inhibition of fusion between lysosomes and Salmonella-containing vacuoles in macrophages. Cell Microbiol. 3, 731-744.
Groisman, E. A., Chiao, E., Lipps, C. J., and Heffron, F. (1989). Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc. Natl. Acad. Sci. U. S. A 86, 7077-7081.
Hardt, W. D., Chen, L. M., Schuebel, K. E., Bustelo, X. R., and Galan, J. E. (1998). S. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. Cell 93, 815-826.
Hensel, M., Shea, J. E., Gleeson, C., Jones, M. D., Dalton, E., and Holden, D. W. (1995). Simultaneous identification of bacterial virulence genes by negative selection. Science 269, 400-403.
Hersh, D., Monack, D. M., Smith, M. R., Ghori, N., Falkow, S., and Zychlinsky, A. (1999). The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc. Natl. Acad. Sci. U. S. A 96, 2396-2401.
Hess, J. and Kaufmann, S. H. (1993). Vaccination strategies against intracellular microbes. FEMS Immunol. Med. Microbiol. 7, 95-103.
Hoiseth, S. K. and Stocker, B. A. (1981). Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291, 238-239.
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, ., Sacks, D., and Desjardins, M. (2003). Phagosomes are competent organelles for antigen cross-presentation. Nature 425, 402-406.
Jones, B. D. and Falkow, S. (1996). Salmonellosis: host immune responses and bacterial virulence determinants. Annu. Rev. Immunol. 14, 533-561.
Kaech, S. M. and Ahmed, R. (2001). Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2, 415-422.
Kaech, S. M., Wherry, E. J., and Ahmed, R. (2002). Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251-262.
Kaufmann, S. H. (1993). Immunity to intracellular bacteria. Annu. Rev. Immunol. 11, 129-163.
Kaufmann, S. H. and Hess, J. (1997). Rational design of antituberculosis vaccines: impact of antigen display and vaccine localization. Biologicals. 25, 169-173.
Kaufmann, S. H., Raupach, B., and Finlay, B. B. (2001). Introduction: microbiology and immunology: lessons learned from Salmonella. Microbes. Infect. 3, 1177-1181.
Krishnan, L., Sad, S., Patel, G. B., and Sprott, G. D. (2000). Archaeosomes induce long-term CD8+cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+T cell help. J. Immunol. 165, 5177-5185.
Lee, S. H. and Galan, J. E. (2003). InvB is a type III secretion-associated chaperone for the Salmonella enterica effector protein SopE. J Bacteriol. 185, 7279-7284.
Luu, R. A., Gurnani, K., Dudani, R., Kammara, R., van Faassen, H., Sirard, J. C., Krishnan, L., and Sad, S. (2006). Delayed expansion and contraction of CD8+ T cell response during infection with virulent Salmonella typhimurium. J. Immunol. 177, 1516-1525.
Miller, S. I., Kukral, A. M., and Mekalanos, J. J. (1989). A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. U. S. A 86, 5054-5058.
Moore, M. W., Carbone, F. R., and Bevan, M. J. (1988). Introduction of soluble protein into the class I pathway of antigen processing and presentation.Cell 54, 777-785.
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J., Zajac, A. J., Miller, J. D., Slansky, J., and Ahmed, R. (1998). Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8, 177-187.
Raupach, B. and Kaufmann, S. H. (2001). Bacterial virulence, proinflammatory cytokines and host immunity: how to choose the appropriate Salmonella vaccine strain? Microbes. Infect. 3, 1261-1269.
Rock, K. L. (1996). A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17, 131-137.
Rosenberg, S. A., Dudley, M. E., and Restifo, N. P. (2008). Cancer immunotherapy. N. Engl. J. Med. 359, 1072.
Russmann, H., Igwe, E. I., Sauer, J., Hardt, W. D., Bubert, A., and Geginat, G. (2001). Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J. Immunol. 167, 357-365.
Russmann, H., Shams, H., Poblete, F., Fu, Y., Galan, J. E., and Donis, R. O. (1998). Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281, 565-568.
Russmann, H., Weissmuller, A., Geginat, G., Igwe, E. I., Roggenkamp, A., Bubert, A., Goebel, W., Hof, H., and Heesemann, J. (2000). Yersinia enterocolitica-mediated translocation of defined fusion proteins to the cytosol of mammalian cells results in peptide-specific MHC class I-restricted antigen presentation. Eur. J. Immunol. 30, 1375-1384.
Schaible, U. E., Winau, F., Sieling, P. A., Fischer, K., Collins, H. L., Hagens, K., Modlin, R. L., Brinkmann, V., and Kaufmann, S. H. (2003). Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med. 9, 1039-1046.
Schumacher, T. N. and Restifo, N. P. (2009). Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 21, 187-189.
Shea, J. E., Hensel, M., Gleeson, C., and Holden, D. W. (1996). Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium. Proc. Natl. Acad. Sci. U. S. A 93, 2593-2597.
Smyth, M. J., Thia, K. Y., Street, S. E., MacGregor, D., Godfrey, D. I., and Trapani, J. A. (2000). Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755-760.
van der Velden, A. W., Lindgren, S. W., Worley, M. J., and Heffron, F. (2000). Salmonella pathogenicity island 1-independent induction of apoptosis in infected macrophages by Salmonella enterica serotype typhimurium. Infect. Immun. 68, 5702-5709.
Yrlid, U. and Wick, M. J. (2000). Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J. Exp. Med. 191, 613-624.
Zhou, D. and Galan, J. (2001). Salmonella entry into host cells: the work in concert of type III secreted effector proteins. Microbes. Infect. 3, 1293-1298.
Zhu, X., Zhou, P., Cai, J., Yang, G., Liang, S., and Ren, D. (2010). Tumor antigen delivered by Salmonella III secretion protein fused withheat shock protein 70 induces protection and eradication against murine melanoma. Cancer Sci. 101, 2621-2628.
Claims (8)
1. A recombinant Salmonella bacterium comprising a nucleic acid encoding a fusion protein comprising:
a) a tumour antigen, a viral antigen, or bacterial antigen; and
b) an N-terminal secretion signal from a type III secretion domain;
wherein the N-terminal secretion signal consists of the sequence set forth in SEQ ID NO: 2.
2. The recombinant bacterium of claim 1 , wherein the fusion protein further comprises a chaperone.
3. The recombinant bacterium of claim 2 , wherein the chaperone is a component of a type III secretion system.
4. The recombinant bacterium of claim 3 , wherein the chaperone is SycE or HSP70.
5. The recombinant bacterium of claim 1 , wherein the nucleic acid is comprised in a vector.
6. The recombinant bacterium of claim 5 , wherein the vector is a pHR vector.
7. The recombinant bacterium of claim 5 , wherein the vector is pHR-241.
8. The recombinant bacterium of claim 1 , wherein the tumour antigen is tyrosinase related protein 2 (TRP-2), MART-1, melanoma associated antigen 1 (MAGE1), Her-2/neu, or gp100.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/369,294 US20170174746A1 (en) | 2010-07-28 | 2016-12-05 | Recombinant Bacterium and Uses Thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36834610P | 2010-07-28 | 2010-07-28 | |
PCT/CA2011/000848 WO2012012872A1 (en) | 2010-07-28 | 2011-07-28 | Recombinant bacterium and uses thereof |
US201313811690A | 2013-01-23 | 2013-01-23 | |
US14/516,090 US9539313B2 (en) | 2010-07-28 | 2014-10-16 | Recombinant bacterium and uses thereof |
US15/369,294 US20170174746A1 (en) | 2010-07-28 | 2016-12-05 | Recombinant Bacterium and Uses Thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/516,090 Continuation US9539313B2 (en) | 2010-07-28 | 2014-10-16 | Recombinant bacterium and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170174746A1 true US20170174746A1 (en) | 2017-06-22 |
Family
ID=45529306
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/811,690 Abandoned US20130156809A1 (en) | 2010-07-28 | 2011-07-28 | Recombinant Bacterium and Uses Thereof |
US14/516,090 Active US9539313B2 (en) | 2010-07-28 | 2014-10-16 | Recombinant bacterium and uses thereof |
US15/369,294 Abandoned US20170174746A1 (en) | 2010-07-28 | 2016-12-05 | Recombinant Bacterium and Uses Thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/811,690 Abandoned US20130156809A1 (en) | 2010-07-28 | 2011-07-28 | Recombinant Bacterium and Uses Thereof |
US14/516,090 Active US9539313B2 (en) | 2010-07-28 | 2014-10-16 | Recombinant bacterium and uses thereof |
Country Status (5)
Country | Link |
---|---|
US (3) | US20130156809A1 (en) |
EP (1) | EP2598631B1 (en) |
CA (1) | CA2806536A1 (en) |
IN (1) | IN2013CN01528A (en) |
WO (1) | WO2012012872A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130273092A1 (en) * | 2010-10-22 | 2013-10-17 | Trudeau Institute | Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells |
EP4019539A1 (en) | 2020-12-22 | 2022-06-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Recombinant bacterium and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068469A1 (en) * | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306387B1 (en) * | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
WO2007044406A2 (en) * | 2005-10-04 | 2007-04-19 | Ludwig Institute For Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
CN101204584A (en) * | 2007-12-17 | 2008-06-25 | 北京娜可长今国际银离子科技开发有限公司 | Tumor vaccine using salmonella as carrier and preparation method thereof |
-
2011
- 2011-07-28 IN IN1528CHN2013 patent/IN2013CN01528A/en unknown
- 2011-07-28 CA CA2806536A patent/CA2806536A1/en not_active Abandoned
- 2011-07-28 EP EP11811675.5A patent/EP2598631B1/en not_active Not-in-force
- 2011-07-28 US US13/811,690 patent/US20130156809A1/en not_active Abandoned
- 2011-07-28 WO PCT/CA2011/000848 patent/WO2012012872A1/en active Application Filing
-
2014
- 2014-10-16 US US14/516,090 patent/US9539313B2/en active Active
-
2016
- 2016-12-05 US US15/369,294 patent/US20170174746A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068469A1 (en) * | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11406702B1 (en) | 2020-05-14 | 2022-08-09 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated Salmonella as a vaccine |
Also Published As
Publication number | Publication date |
---|---|
EP2598631A4 (en) | 2014-10-08 |
EP2598631B1 (en) | 2019-04-10 |
WO2012012872A1 (en) | 2012-02-02 |
IN2013CN01528A (en) | 2015-07-03 |
US9539313B2 (en) | 2017-01-10 |
EP2598631A1 (en) | 2013-06-05 |
CA2806536A1 (en) | 2012-02-02 |
US20130156809A1 (en) | 2013-06-20 |
US20150140028A1 (en) | 2015-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11446369B2 (en) | Compositions and methods comprising KLK3 or FOLH1 antigen | |
JP6182172B2 (en) | Dual delivery system for xenoantigens | |
EP2283112B1 (en) | Compositions comprising prfa*mutant listeria and methods of use thereof | |
ES2566392T3 (en) | Listeria-based and LLO-based vaccines | |
US9017660B2 (en) | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors | |
KR20170028363A (en) | Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof | |
TW201723171A (en) | Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment | |
US20180360940A1 (en) | Listeria-based immunotherapy and methods of use thereof | |
US20170174746A1 (en) | Recombinant Bacterium and Uses Thereof | |
EP3303593A1 (en) | Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors | |
AU2018235153A1 (en) | Novel PD-L1 targeting DNA vaccine for cancer immunotherapy | |
SMITH | Patent 2806536 Summary | |
JP6329211B2 (en) | Use of recombinant Listeria strains in the manufacture of a medicament for delaying the onset of brain tumors or breast tumors | |
WO2017040859A1 (en) | Methods and compositions for modulating prfa mediated virulence gene activation in listeria spp. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |